Charles River Laboratories International, Inc. (CRL) 2026 Q2 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Ladies and gentlemen, thank you for standing by, and welcome to the Charles River Laboratories second-quarter 2026 earnings conference call. This call is being recorded. (Operator Instructions)

    各位女士、先生,感謝您稍候,歡迎參加 Charles River Laboratories 2026 年第二季財報電話會議。本次通話將被錄音。(接線員指示)

  • I would now like to turn the conference over to our host, Todd Spencer, Vice President of Investor Relations. Please go ahead.

    現在我想把會議交給我們的主持人——投資人關係副總裁 Todd Spencer。請開始。

  • Todd Spencer - Corporate Vice President, Investor Relations

    Todd Spencer - Corporate Vice President, Investor Relations

  • Good morning, and welcome to Charles River Laboratories second-quarter 2026 earnings conference call and webcast. This morning, I am pleased to be joined by Birgit Girshick, our Chief Executive Officer; and by Glenn Coleman, our Executive Vice President and Chief Financial Officer. They will comment on our results for the second-quarter of 2026 as well as our financial guidance.

    各位早安,歡迎參加 Charles River Laboratories 2026 年第二季財報電話會議與網路直播。今天早上,我很高興與各位一同出席的有:我們的執行長 Birgit Girshick,以及我們的執行副總裁兼財務長 Glenn Coleman。他們將就 2026 年第二季的業績以及我們的財務指引發表評論。

  • Following the presentation, they will respond to questions. There is a slide presentation associated with today's remarks, which will be posted on the Investor Relations section of our website at ir.criver.com. A webcast replay of this call will be available beginning approximately two hours after the call today and can be accessed on our Investor Relations website.

    在簡報之後,他們將回應提問。今天的發言搭配一份投影片簡報,將發布於我們網站 ir.criver.com 的投資人關係專區。本次電話會議的網路重播將於今日通話結束約兩小時後提供,並可於我們的投資人關係網站上收看。

  • The replay will be available through next quarter's conference call. I'd like to remind you of our safe harbor. All remarks that we make about future expectations, plans and prospects for the company constitute forward-looking statements under the Private Securities Litigation Act of 1995. Actual results may differ materially from those indicated.

    重播將提供至下一季的財報電話會議為止。我想提醒各位注意我們的「安全港」聲明。我們對公司未來預期、計畫與前景所做的所有評論,均構成《1995 年私人證券訴訟改革法》所定義的前瞻性陳述。實際結果可能與所示內容有重大差異。

  • During this call, we will primarily discuss non-GAAP financial measures, which we believe help investors gain a meaningful understanding of our core operating results and guidance. The non-GAAP financial measures are not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP. In accordance with Regulation G, you can find the comparable GAAP measures and the reconciliation on the Investor Relations section of our website.

    在本次通話中,我們將主要討論非 GAAP 財務衡量指標;我們相信這些指標有助於投資人更有意義地理解我們的核心營運結果與指引。非 GAAP 財務衡量指標並非意在被視為優於或可替代依 GAAP 編製的營運結果。依據 Regulation G,您可在我們網站的投資人關係專區找到可比的 GAAP 指標及其調節表。

  • I will now turn the call over to Birgit Girshick.

    現在我把電話交給 Birgit Girshick。

  • Birgit Girshick - Chief Executive Officer

    Birgit Girshick - Chief Executive Officer

  • Thank you, Todd, and good morning. Today, I would like to discuss the progress that we made during the second-quarter, both financially and on our refreshed strategic framework pathway to purpose. I'm pleased to report that we delivered on our second-quarter financial targets, exceeding our prior outlook for the quarter and that we are raising our financial guidance for the year.

    謝謝你,Todd,各位早安。今天,我想討論我們在第二季所取得的進展,包含財務面以及我們更新後的策略架構「Pathway to Purpose(使命之路)」上的推進。我很高興報告,我們達成了第二季的財務目標,且表現超出先前對本季的展望,同時我們也上調了全年財務指引。

  • We continue to remain focused on execution on achieving our financial targets and driving increased shareholder value as well as executing on our pathway to purpose strategy which includes working to modernize our company and the industry, strengthening our world-class scientific portfolio and offering a customized client-centric approach to drive growth. Execution of our pathway to purpose strategic initiatives and our financial goals will be the key to our future success.

    我們仍持續專注於執行,以達成財務目標並提升股東價值,同時推動「使命之路」策略;該策略包括致力於推動公司與產業現代化、強化我們世界級的科學產品組合,並提供量身打造、以客戶為中心的方法以帶動成長。「使命之路」策略倡議與財務目標的落實執行,將是我們未來成功的關鍵。

  • Let me now provide you with the recent highlights that demonstrate our progress on our pathway to purpose initiatives as well as our second-quarter performance. First, we were encouraged that the biopharmaceutical demand environment continued to strengthen in the second-quarter, particularly in the DSA segment.

    接下來我將分享近期重點,說明我們在「使命之路」倡議以及第二季表現上的進展。首先,我們受到鼓舞的是,生物製藥需求環境在第二季持續轉強,尤其是在 DSA 事業部門。

  • The DSA net book-to-bill rose to nearly 1.2 times in the second-quarter, making this the third consecutive quarter that the DSA net book-to-bill has been above one times and our highest level achieved in nearly four years. Our constructive view was also supported by a return to organic revenue growth of 0.1% for the total company, which marks the first time that revenue has improved organically since the third-quarter of 2023.

    第二季 DSA 淨接單出貨比(net book-to-bill)上升至接近 1.2 倍,這是 DSA 淨接單出貨比連續第三季高於 1 倍,也是近四年來的最高水準。我們的正向看法亦受到支持:全公司有機營收成長回升至 0.1%,這是自 2023 年第三季以來,營收首次出現有機改善。

  • We firmly believe these trends position us well to drive higher organic growth during the second half of the year. As part of our efforts to further deepen client relationships, in June, we announced a unique collaboration with Eli Lilly's TuneLab drug discovery platform. In support of Lilly's goal to advance R&D modernization efforts, we will provide our nonclinical or wet lab testing expertise to help build and optimize Eli Lilly's AI and machine learning drug discovery model.

    我們堅信,這些趨勢使我們處於有利位置,可在下半年推動更高的有機成長。作為進一步深化客戶關係努力的一部分,我們於 6 月宣布與 Eli Lilly 的 TuneLab 藥物發現平台展開一項獨特合作。為支持 Lilly 推進研發現代化的目標,我們將提供非臨床(nonclinical)或濕實驗室(wet lab)測試專業能力,協助建置並優化 Eli Lilly 的 AI 與機器學習藥物發現模型。

  • We believe this type of collaboration demonstrates that the future state of drug discovery and development will require traditional in vivo and in vitro solutions even when integrated with AI or other in silico approaches to help enhance the speed and scientific data needed to support our clients' R&D programs. And Charles River is a scientific partner that is uniquely positioned to be able to integrate traditional in vivo, in vitro and new innovative capabilities into one comprehensive solution for the biopharmaceutical industry.

    我們相信,這類合作顯示藥物發現與開發的未來樣貌,即使與 AI 或其他電腦模擬(in silico)方法整合,仍需要傳統的體內(in vivo)與體外(in vitro)解決方案,以提升速度並提供支持客戶研發計畫所需的科學數據。而 Charles River 作為科學合作夥伴,具備獨特優勢,能將傳統的 in vivo、in vitro 與新的創新能力整合為一套面向生物製藥產業的完整解決方案。

  • We are also utilizing new technologies, including AI, to modernize and strengthen our own scientific portfolio, including an enhanced digital pathology solution that delivers AI-enabled end-to-end workflows designed to improve study turnaround times and increase pathologists' efficiency. With over 140 trained pathologists on staff, pathology always has been one of Charles River's greatest strength.

    我們也正運用包括 AI 在內的新技術,來推動自身科學產品組合的現代化與強化,其中包括升級的數位病理解決方案,提供 AI 賦能的端到端工作流程,旨在改善研究週轉時間並提升病理醫師效率。我們擁有超過 140 位受訓病理醫師,病理學一直是 Charles River 最重要的優勢之一。

  • And this enhanced digital solution will drive both internal operating efficiency and greater speed for our clients' programs. On goal for clients that utilize our fully integrated digital pathology solution will be to cut at least one week from standard pathology time lines. As I discussed in detail last quarter, we completed the divestitures of certain European discovery services sites in May 2026 as well as the CDMO and Cell Solutions businesses.

    而這項強化的數位解決方案將同時提升內部營運效率,並為客戶計畫帶來更快速度。對於使用我們完整整合式數位病理解決方案的客戶而言,我們的目標是將標準病理時程至少縮短一週。如我在上季詳細說明,我們已於 2026 年 5 月完成出售部分歐洲探索服務據點,以及 CDMO 與 Cell Solutions 業務。

  • The partial quarter benefit from the divestitures was one of the drivers of the 420 basis points of sequential operating margin improvement in the second-quarter to 20.5% and helps us refine the portfolio to create a more streamlined offering focused on our core competencies in regulated testing solutions. We are also continuing to invest organically in our scientific capabilities to support our future growth and accommodate more of the testing requirements for our clients' therapeutic programs including in the area of lab sciences and specifically bioanalysis.

    出售資產帶來的部分季度效益,是第二季營業利益率較前一季提升 420 個基點、至 20.5% 的驅動因素之一,並有助於我們精煉產品組合,打造更精簡的服務供給,聚焦於我們在受監管測試解決方案(regulated testing solutions)方面的核心能力。我們也持續以有機方式投資於科學能力,以支持未來成長,並承接客戶治療計畫更多的測試需求,包括在實驗室科學領域,尤其是生物分析(bioanalysis)。

  • Demand for lab science services has been growing nicely over the past 5 years, driven by large molecule, bioanalysis, biomarkers and additional testing requirements in both regulated and nonregulated programs, including in the clinical development phase. To support this growth, we recently embarked on an expansion to add bioanalytical laboratory capacity at Heriot Watt University's Research Park in Scotland.

    過去 5 年來,實驗室科學服務需求成長良好,主要受大分子、生物分析、生物標記(biomarkers)以及在受監管與非受監管計畫中的額外測試需求所帶動,其中也包括臨床開發階段。為支持此成長,我們近期啟動擴建計畫,將在蘇格蘭 Heriot Watt 大學研究園區增加生物分析實驗室產能。

  • This expansion, which is one of five ongoing lab sciences expansions globally at Charles River will also offer an opportunity to partner with Harriet Watt University on the talent pipeline to further support our future growth in bioanalysis and in the region. My final highlight demonstrates how our broader strategy is working to support our client-centric approach.

    此項擴建是 Charles River 全球五項進行中的實驗室科學擴建計畫之一,同時也提供與 Heriot Watt 大學在人才管道方面合作的機會,以進一步支持我們在生物分析及該地區的未來成長。我最後一項重點將展示我們更廣泛的策略如何支持以客戶為中心的方法。

  • We recently announced a collaboration with Arovella Therapeutics to provide next-generation sequencing or NGS services to accelerate progress towards their alternative cancer treatment approaches using cell and gene therapy. This collaboration shows that by strengthening our scientific capabilities with an innovative in vitro NGS testing solution through our recent acquisition of PathoQuest, we are able to deepen client relationships and expand the possible opportunities for collaboration.

    我們近期宣布與 Arovella Therapeutics 合作,提供次世代定序(NGS)服務,以加速其以細胞與基因治療推進替代性癌症治療方法的進展。此合作顯示,透過近期收購 PathoQuest、以創新的 in vitro NGS 測試解決方案強化我們的科學能力,我們得以深化客戶關係並擴大可能的合作機會。

  • In today's dynamic marketplace, there are abundant opportunities to further differentiate Charles River from the competition. We stand along with our strong financial profile, refreshed strategic vision and scientific expertise focused on our core regulated testing capabilities that span early-stage development through the clinic and beyond.

    在今日充滿動態的市場環境中,存在大量機會可進一步讓 Charles River 與競爭對手區隔。憑藉我們強健的財務體質、更新後的策略願景,以及聚焦於核心受監管測試能力的科學專業(涵蓋從早期開發到臨床及其後續階段),我們已做好準備。

  • Clients are expecting their scientific partners to help them drive greater innovation, speed and efficiency, and we are making great progress under our pathway to purpose strategic framework to become an even more modern client-centric organization that will operate more simply with more agility and enhanced digital connectivity.

    客戶期望其科學合作夥伴協助推動更高的創新、速度與效率;我們在「以使命為導向的路徑」(pathway to purpose)策略架構下取得了顯著進展,正邁向成為更現代、以客戶為中心的組織,以更簡化的方式運作、具備更高的敏捷性,並強化數位連結能力。

  • As the biopharma demand environment improves, this will enable us to become an even more essential partner to our clients, work with them across our differentiated portfolio and gain a greater share of their R&D spend. Let me provide a brief update on the end market trends. As I mentioned, we believe the biopharma demand is continuing to sustainably improve.

    隨著生物製藥需求環境改善,這將使我們成為客戶更不可或缺的合作夥伴,能在我們具差異化的產品組合上與其展開更廣泛合作,並取得其研發支出中更高的份額。我先簡要更新終端市場趨勢。如我所提及,我們認為生物製藥需求正持續且可持續地改善。

  • Small and midsized biotech clients are leading the trend as a result of the invigorated funding environment demonstrated by a trailing 12-month funding of nearly $100 billion which is just shy of peak levels achieved during the pandemic. While we continue to monitor for changes in the funding environment, whether it be from interest rates and inflation pressures or other macroeconomic factors, funding activity has been resilient and broad-based to date, including a notable increase in IPO activity as well as solid VC and follow-on funding.

    在過去12個月的資金募集接近1,000億美元(略低於疫情期間達到的高峰)所反映的資金環境回溫帶動下,中小型生技客戶正引領此一趨勢。雖然我們持續監測資金環境的變化(無論是利率與通膨壓力或其他總體經濟因素),但迄今資金活動仍具韌性且範圍廣泛,包括IPO活動顯著增加,以及穩健的創投(VC)與後續融資。

  • Overall, revenue from small and midsized biotechs was essentially flat organically in the second-quarter, which is an improvement from declines in recent quarters. As a reminder, there is a natural lag of several quarters between studies are booked into backlog and work their way through to revenue. So we're just beginning to see the benefit from improved DSA booking activity from late last year.

    整體而言,第二季來自中小型生技公司的營收以有機基礎計算大致持平,較近期幾季的下滑有所改善。提醒一下,研究案自接單納入在手訂單(backlog)到逐步轉化為營收,通常存在數季的自然落後期。因此,我們才剛開始看到去年底以來DSA接單活動改善所帶來的效益。

  • Therefore, the strengthening booking activity that we have experienced through the middle of this year gives us greater confidence that we will generate incremental organic revenue growth starting in the third-quarter on both a consolidated basis and in the DSA segment. Global biopharmaceutical clients were also a significant contributor to the improving DSA demand KPIs in the second-quarter.

    因此,截至今年年中我們所經歷的接單活動走強,使我們更有信心自第三季起,無論在合併層級或DSA事業部門,都將開始帶來額外的有機營收成長。全球生物製藥客戶亦是第二季DSA需求KPI改善的重要貢獻者。

  • As I mentioned last quarter, most of our global biopharma clients have progressed through restructuring and pipeline reprioritization activities over the last several years. Demand trends have been improving gradually over the last 18 months with a continued evidence this year. Revenue from global biopharmaceutical clients continued to increase organically in the second-quarter.

    如我在上季所提,多數全球生物製藥客戶在過去數年已完成重整與產品線(pipeline)優先順序重排等工作。過去18個月需求趨勢逐步改善,今年亦持續出現相關證據。第二季來自全球生物製藥客戶的營收以有機基礎計算持續增加。

  • I will now provide some highlights from our financial performance before Glenn provides additional detail. First, we are pleased that our second-quarter results exceeded our prior outlook for revenue and non-GAAP earnings per share. second-quarter revenue increased 0.1% on an organic basis compared to our prior outlook of a low single-digit decline.

    在Glenn提供更多細節之前,我先說明我們財務表現的幾項重點。首先,我們很高興第二季營收與非GAAP每股盈餘均優於先前展望。第二季營收以有機基礎計算年增0.1%,相較我們先前預期的低個位數下滑更佳。

  • In addition to the solid top line performance, the operating margin increased 420 basis points sequentially to 20.5% due to two primary factors: First, less pressure from several discrete margin headwinds that impacted the first-quarter as we had anticipated. And second, a partial quarter benefit from the divestitures that enabled the Manufacturing segment's operating margin to jump to 37.8% in the second-quarter.

    除穩健的營收表現外,營業利益率亦較前一季提升420個基點至20.5%,主要來自兩項因素:第一,如我們所預期,第一季受到影響的數項一次性(discrete)毛利逆風在第二季壓力減輕。第二,資產處分帶來的部分季度效益,使製造(Manufacturing)事業部門第二季營業利益率跳升至37.8%。

  • For the remainder of the year, we continue to have a clear line of sight into the drivers behind at least 500 basis points of margin improvement expected in the second half of the year with the largest drivers being the actions that we have already taken to strengthen and refine our portfolio. Non-GAAP earnings per share of $3.02 increased 47% sequentially, which was well above our prior outlook of at least 30% sequential growth.

    就今年剩餘期間而言,我們仍能清楚掌握下半年預期至少提升500個基點的利益率改善驅動因素,其中最大動能來自我們已採取的行動,以強化並精煉我們的產品組合。非GAAP每股盈餘為3.02美元,較前一季成長47%,明顯高於我們先前至少30%季增的展望。

  • Glenn will provide more details on the operating margin and earnings drivers in a moment as well as our increased financial guidance. RMS revenue declined 1.4% organically. This represents an improvement from the first-quarter level due principally to the timing of NHP shipments, which were more normalized in the second-quarter and did not have a meaningful impact on the year-over-year growth rate.

    Glenn稍後將就營業利益率與獲利驅動因素,以及我們上調後的財務指引提供更多細節。RMS營收以有機基礎計算下滑1.4%。相較第一季,這代表有所改善,主要原因在於NHP出貨時點;第二季出貨較為正常化,對年增率未造成顯著影響。

  • The primary drivers of the year-over-year revenue decline were lower revenue for small models in North America as well as for research model services, including Genetically Engineered Models & Services or GEMS. These declines were largely offset by continued robust demand for research models in China from mid-tier biotech and CRO clients.

    年對年營收下滑的主要驅動因素為北美小型模式(small models)營收下降,以及研究模型服務(research model services)營收下降,包括基因工程模型與服務(Genetically Engineered Models & Services,GEMS)。上述下滑多數被中國中型生技與CRO客戶對研究模型的持續強勁需求所抵銷。

  • For the year, we continue to expect a low to mid-single-digit organic revenue decline in the RMS segment, with much of this decline driven by lower volumes for research models in North America. This is largely because spending from academic and government clients has been constrained by flat NIH budgets and slower grant processing.

    就全年而言,我們仍預期RMS事業部門有機營收將呈低至中個位數下滑,其中多數下滑來自北美研究模型出貨量降低。這主要是因為學術與政府客戶的支出受限於NIH預算持平以及補助金審核流程較慢。

  • DSA revenue returned to growth, increasing 0.2% organically in the second-quarter. As noted, it takes several quarters for projects booked to work through the backlog and into the revenue stream. So we are just beginning to see the benefits of the improved biopharmaceutical demand trends from the end of last year.

    DSA營收恢復成長,第二季以有機基礎計算增加0.2%。如前所述,專案自接單後需經過數季才會從在手訂單逐步轉入營收。因此,我們才剛開始看到去年底以來生物製藥需求趨勢改善所帶來的效益。

  • The second-quarter improvement was broadly driven across multiple study types and modalities, including a more discernible uptick in IND-enabling studies as clients shift their research focus earlier to replenish their pipelines and continued strength for NHP-related studies, reflecting our clients' focus on complex biologics. Regulatory required safety assessment studies utilizing NHPs have become a competitive advantage for Charles River because of our more reliable supply of these critical research models after strengthening our portfolio through the acquisitions of suppliers in Cambodia and Mauritius in recent years.

    第二季的改善廣泛來自多種研究類型與技術平台(modalities),包括IND申請前(IND-enabling)研究出現更明顯的回升,因客戶將研發重心前移以補充其產品線;同時,與NHP相關研究持續強勁,反映客戶聚焦於高複雜度生物製劑。由於我們在近年透過收購柬埔寨與模里西斯的供應商來強化產品組合,對這些關鍵研究模型具更可靠的供應,使得使用NHP的法規要求安全性評估研究成為Charles River的競爭優勢。

  • We expect the DSA growth rate to accelerate in the second half of the year, supported by encouraging trends in the DSA demand environment to date. Net bookings increased significantly year-over-year and by 12.6% sequentially to $701 million in the second-quarter, resulting in an increase in the DSA backlog to $1.97 billion and a net book-to-bill of 1.19 times.

    我們預期DSA成長率將在下半年加速,並受迄今DSA需求環境的正向趨勢所支撐。第二季淨接單(net bookings)年增顯著,且較前一季成長12.6%至7.01億美元,帶動DSA在手訂單增至19.7億美元,淨接單出貨比(net book-to-bill)為1.19倍。

  • The second-quarter improvement was broad-based across both global biopharmaceutical and small and midsized biotechnology client segments. As noted, these were the highest levels for the net book-to-bill and net bookings in nearly four years since the third-quarter of 2022 and the third consecutive quarter that the net book-to-bill was above one times.

    第二季的改善同時來自全球生物製藥客戶與中小型生技客戶兩大族群,呈現廣泛性。如前所述,淨接單出貨比與淨接單均為近四年來的最高水準(自2022年第三季以來),且淨接單出貨比已連續第三季高於1倍。

  • These trends, combined with another strong increase in proposal activity during the second-quarter, leave us cautiously optimistic that the positive momentum will continue. Underlying DSA market demand is improving as supported by the recent strength in biotech funding and the improvement in our KPIs. In this environment, we continue to differentiate ourselves in the marketplace through our financial stability, scientific expertise, global scale and digitized client experience, which accelerates the speed with which we are able to work with our clients and enables us to take share.

    這些趨勢,再加上第二季提案活動(proposal activity)再度強勁增加,使我們在審慎態度下保持樂觀,認為正向動能可望延續。在近期生技融資走強及我們KPI改善的支持下,DSA市場的底層需求正在改善。在此環境下,我們憑藉財務穩健、科學專業、全球規模與數位化客戶體驗持續在市場上展現差異化;這加快了我們與客戶合作的速度,並使我們能夠提升市占。

  • As a result of these collective trends, we have raised our DSA outlook to low single-digit organic revenue growth in 2026. That said, we continue to expect the recovery will be marked by gradual progress. Manufacturing revenue increased 1.3% organically. Revenue for Microbial Solutions continued to increase at a high single-digit rate in the second-quarter, partially offset by more modest growth in the Biologics Testing business.

    基於上述整體趨勢,我們已將2026年DSA展望上調至低個位數的有機營收成長。儘管如此,我們仍預期復甦將以循序漸進的方式推進。製造(Manufacturing)營收以有機基礎計算成長1.3%。第二季微生物解決方案(Microbial Solutions)營收持續以高個位數成長,部分被生物製劑檢測(Biologics Testing)業務較為溫和的成長所抵銷。

  • The manufacturing organic growth rate is expected to improve to mid- to high single-digit rates in the second half of the year when the biologic testing growth rate rebounds after we anniversary a client-specific challenge that has been a headwind since the middle of last year. In addition, CDMO was also a headwind to organic growth for the partial quarter because it wasn't divested until May.

    預期製造業務的有機成長率將在下半年改善至中至高個位數,屆時在我們度過一項自去年年中以來一直造成逆風的特定客戶挑戰之周年後,生物製劑測試的成長率將回升。此外,由於 CDMO 直到 5 月才完成剝離,因此在該季度的部分期間也對有機成長造成逆風。

  • As I close today, I want to share a reflection for my first few months as CEO. I've had the privilege of visiting more than 40 Charles River sites across 7 countries, meeting with employees in town hall and individual settings and hearing firsthand about their work, their challenges and their ideas. What struck me most was the consistent passion, commitment and sense of purpose I saw everywhere I went.

    在我今天結語時,我想分享我擔任執行長最初幾個月的一些感想。我有幸走訪了 7 個國家超過 40 個 Charles River 據點,透過員工大會及個別交流與同仁會面,第一手聽取他們的工作內容、面臨的挑戰以及提出的想法。最令我印象深刻的是,無論我走到哪裡,都能感受到一致的熱情、承諾與使命感。

  • Those conversations left me even more confident in the future of Charles River and our ability to deliver long-term success for our clients and shareholders and the patients we ultimately serve. They also reinforced for me how critical our pathway to purpose strategy is in guiding our decisions, strengthening our culture and positioning the company for sustainable growth. I remain incredibly optimistic about what we can achieve together and look forward to building on the strong foundation we have created.

    這些對話讓我對 Charles River 的未來,以及我們為客戶與股東、以及最終所服務的病患帶來長期成功的能力,更加充滿信心。同時也再次讓我體認到,我們的「通往使命(pathway to purpose)」策略在引導決策、強化文化並使公司具備可持續成長定位方面有多麼關鍵。我仍對我們能共同達成的成果抱持極度樂觀,並期待在我們已建立的堅實基礎上持續發展。

  • Now I will turn the call over to Glenn to provide more details on our second-quarter financial performance as well as our 2026 guidance.

    接下來我將把電話會議交給 Glenn,請他提供第二季財務表現以及我們 2026 年指引的更多細節。

  • Glenn Coleman - Chief Financial Officer, Executive Vice President

    Glenn Coleman - Chief Financial Officer, Executive Vice President

  • Thank you, Birgit, and good morning. As a reminder, my comments on financial performance will largely be related to non-GAAP results, which exclude amortization and other acquisition and divestiture-related adjustments, costs related primarily to restructuring and efficiency initiatives and certain other items. Many of my comments will also refer to organic revenue growth, which excludes the impact of acquisitions, divestitures and foreign currency translation.

    謝謝你,Birgit,大家早安。提醒各位,我對財務表現的評論將主要以非 GAAP 結果為主,該結果排除攤銷及其他與併購與剝離相關的調整、主要與重整及效率提升計畫相關的成本,以及若干其他項目。我也會多次提到有機營收成長,該指標排除併購、剝離及外幣換算的影響。

  • We are pleased with our financial performance for the second-quarter with both revenue and non-GAAP earnings per share exceeding our prior outlook. On an organic basis, revenue was essentially flat year-over-year compared to our prior forecast of a low single-digit decline, driven by better-than-expected performance in our DSA and Manufacturing segments.

    我們對第二季的財務表現感到滿意,營收與非 GAAP 每股盈餘均高於先前展望。以有機基礎計算,營收年增率基本持平,相較於我們先前預估的低個位數下滑更佳,主要受惠於 DSA 與 Manufacturing 事業群表現優於預期。

  • The non-GAAP operating margin of 20.5% was in line with our forecast, but improved by 420 basis points on a sequential basis over the first-quarter. Non-GAAP earnings per share of $3.02 also exceeded our expectations with over half of the outperformance driven by better-than-expected top line results and the remainder by a favorable contribution from nonoperating items, which I'll discuss in more detail shortly.

    非 GAAP 營業利益率 20.5% 符合我們的預測,但相較第一季按季提升 420 個基點。非 GAAP 每股盈餘為 3.02 美元,也超出我們預期;其中超過一半的優於預期來自營收表現優於預期,其餘則來自非營業項目的有利貢獻,我稍後會更詳細說明。

  • In the second-quarter, we also repurchased $100 million in shares at approximately $174 per share under the $1 billion stock repurchase authorization approved last October. This brings our total year-to-date share repurchases to $300 million and reflects the continuation of our thoughtful and diligent approach to capital deployment to enhance shareholder value as we balance organic investments in the business, pursue strategic acquisitions and repay debt.

    第二季我們也在去年 10 月核准的 10 億美元庫藏股回購授權下,以每股約 174 美元回購了 1 億美元的股票。這使得今年迄今的股票回購總額達到 3 億美元,並反映我們在資本配置上持續採取審慎且嚴謹的方法,以在平衡業務的有機投資、追求策略性併購以及償還債務的同時,提升股東價值。

  • Our updated guidance assumes an average diluted share count of approximately 48.5 million shares for the full year 2026. Moving to details on our segment performance. DSA revenue was $607 million in the second-quarter, a decrease of 1.9% on a reported basis compared to the second-quarter of 2025 due primarily to the impact of the divestiture of certain European discovery sites.

    我們更新後的指引假設 2026 全年平均稀釋後流通股數約為 4,850 萬股。接著說明各事業群表現細節。DSA 第二季營收為 6.07 億美元,按報表口徑較 2025 年第二季下降 1.9%,主要是因為剝離部分歐洲 discovery 據點的影響。

  • On an organic basis, revenue increased 0.2% and was also the first time we reported organic growth in DSA since the third-quarter of 2023. Year-over-year, operating margin decreased by 180 basis points to 25.6%, however, increased by 460 basis points on a sequential basis from the first-quarter. The year-over-year decline was primarily due to higher study-related direct costs.

    以有機基礎計算,營收成長 0.2%,這也是自 2023 年第三季以來我們首次在 DSA 報告有機成長。年對年而言,營業利益率下降 180 個基點至 25.6%;但相較第一季按季提升 460 個基點。年對年的下滑主要是因研究相關的直接成本較高所致。

  • However, we expect this year-over-year margin headwind to turn favorable in the coming quarters as we benefit from lower NHP sourcing costs as a result of the acquisition of our Cambodian NHP supplier. The lower sourcing costs for Cambodian NHPs will begin to benefit the DSA operating margin in the third-quarter, but will have a more significant margin contribution in the fourth-quarter as we increase our use of these models on studies.

    然而,我們預期這項年對年毛利率逆風將在未來幾季轉為有利,因為我們將受惠於收購柬埔寨 NHP 供應商後帶來的較低 NHP 採購成本。柬埔寨 NHP 較低的採購成本將於第三季開始對 DSA 營業利益率帶來助益,但在第四季隨著我們在研究中增加使用這些模型,對利潤率的貢獻將更為顯著。

  • As a result, we expect the operating margin in DSA to be the highest in the fourth-quarter. Shifting to the RMS segment. Revenue was $209 million in the quarter, representing an organic decline of 1.4% year-over-year. Small model revenue experienced lower volume for research models in North America and for research model services, partially offset by continued strong demand in China.

    因此,我們預期 DSA 的營業利益率將在第四季達到全年最高。接著談 RMS 事業群。本季營收為 2.09 億美元,年對年有機下滑 1.4%。小型模型營收方面,北美研究模型與研究模型服務的出貨量較低,但部分被中國持續強勁的需求所抵銷。

  • Operating margin declined by 80 basis points to 24.5% in the second-quarter due largely to the impact of lower sales volume and an unfavorable geographic revenue mix. Wrapping up the segment performance, the Manufacturing segment reported second-quarter revenue of $188 million, an increase of 1.3% on an organic basis.

    第二季營業利益率下降 80 個基點至 24.5%,主要受到銷售量較低以及不利的地區營收組合影響。最後是 Manufacturing 事業群,第二季營收為 1.88 億美元,以有機基礎計算成長 1.3%。

  • The CDMO business reduced the segment organic revenue growth rate by nearly 400 basis points in the quarter, with the segment growing at a mid-single-digit organic growth rate, excluding CDMO. The strong performance in our Manufacturing segment was largely driven by high single-digit organic growth in our Microbial Solutions business as we saw increases in demand across our three major geographic regions for endotoxin testing reagents, including our PTS rapid testing cartridges as well as adding new clients to our strong broad-based quality control testing platform.

    CDMO 業務在本季使該事業群的有機營收成長率降低了近 400 個基點;若排除 CDMO,該事業群以中個位數的有機成長率成長。Manufacturing 事業群的強勁表現主要由 Microbial Solutions 業務的高個位數有機成長所帶動;我們看到三大主要地理區域對內毒素檢測試劑的需求增加,包括我們的 PTS 快速檢測卡匣,同時也為我們強健且廣泛的品質控制檢測平台新增客戶。

  • Operating margin improved by 500 basis points year-over-year to 37.8%, driven primarily by the benefit of the CDMO divestiture. We expect the Manufacturing segment to remain a meaningful contributor to margin expansion during the second half of the year with the operating margin approaching 40% with the full benefit being recognized from the CDMO divestiture.

    營業利益率年對年提升 500 個基點至 37.8%,主要受惠於 CDMO 剝離。我們預期在下半年 Manufacturing 事業群仍將是利潤率擴張的重要貢獻者;隨著 CDMO 剝離效益全面反映,營業利益率將接近 40%。

  • Moving on to other financial metrics. Unallocated corporate costs were higher than expected in the second-quarter, totaling $72 million or 7.2% of revenue compared to 5.9% in the prior year period. The increase was primarily driven by increased costs related to our deferred compensation plan of $6 million or $0.10 per share due to the market performance of the plan assets during the quarter.

    接著說明其他財務指標。第二季未分攤的公司成本高於預期,合計 7,200 萬美元,占營收 7.2%,相較去年同期為 5.9%。增加主要來自與我們遞延補償計畫相關的成本上升 600 萬美元(或每股 0.10 美元),原因是該計畫資產在本季的市場表現所致。

  • To fund the deferred compensation plan, we separately invest in certain funds, which experienced gains of $19 million or $0.29 per share in the second-quarter. These gains are included in other income. The net benefit associated with our deferred compensation plan was $0.19 per share in the second-quarter, which we do not expect to recur.

    為了資助遞延補償計畫,我們另行投資於特定基金,第二季產生 1,900 萬美元(或每股 0.29 美元)的收益。這些收益列入其他收入。第二季與遞延補償計畫相關的淨受益為每股 0.19 美元,我們預期此情況不會再發生。

  • Based upon our second-quarter results and updated forecast, which also encompasses higher performance-based compensation, we now expect unallocated corporate costs of approximately 6.0% of revenue for the full year compared to our prior outlook of approximately 5.5%. Net interest expense was $28 million in the second-quarter, a decline of $1.2 million year-over-year.

    基於第二季結果與更新後的預測(亦包含較高的績效型薪酬),我們目前預期全年未分攤公司成本約占營收 6.0%,高於先前約 5.5% 的展望。第二季淨利息費用為 2,800 萬美元,年對年減少 120 萬美元。

  • For the full year, our net interest expense outlook remains unchanged at $103 million to $108 million on a non-GAAP basis. At the end of the second-quarter, our net leverage improved slightly to 2.5x from the first-quarter. The non-GAAP tax rate in the second-quarter was 23.8%, an increase of 110 basis points year-over-year due primarily to the impact of discrete items.

    就全年而言,我們的淨利息費用展望在非 GAAP 基礎上維持不變,為 1.03 億至 1.08 億美元。在第二季末,我們的淨槓桿較第一季略有改善,降至 2.5 倍。第二季非 GAAP 稅率為 23.8%,年增 110 個基點,主要由一次性(離散)項目的影響所致。

  • For the full year, we now anticipate our non-GAAP tax rate will be in the range of 23% to 24%, an increase of approximately 100 basis points from our prior outlook, primarily as a result of the unfavorable second-quarter rate and a higher tax rate due to proposed tax legislation changes in a foreign tax jurisdiction. The higher tax rate outlook for the year is expected to be a $0.20 headwind to earnings per share with about half of the impact in the third-quarter.

    就全年而言,我們目前預期非 GAAP 稅率將落在 23% 至 24% 的區間,較先前展望上調約 100 個基點,主要是由於第二季不利的稅率,以及因海外稅務管轄區擬議稅法變更而導致的較高稅率。預期全年較高的稅率展望將對每股盈餘造成 0.20 美元的不利影響,其中約一半的影響將發生在第三季。

  • Free cash flow was $149 million in the second-quarter, a decrease of $21 million compared to the prior year period. This decline was primarily driven by the timing of working capital. CapEx declined to $31 million or approximately 3.1% of revenue in the second-quarter from $35 million last year. For the full year, we're raising our free cash flow projections to be in the range of $400 million to $420 million compared to our prior outlook of $375 million to $400 million, largely driven by higher earnings.

    第二季自由現金流為 1.49 億美元,較去年同期減少 2,100 萬美元。此下滑主要由營運資金時點所驅動。第二季資本支出(CapEx)降至 3,100 萬美元,約占營收 3.1%,低於去年同期的 3,500 萬美元。就全年而言,我們將自由現金流預測上調至 4.00 億至 4.20 億美元,先前展望為 3.75 億至 4.00 億美元,主要由較高的獲利所帶動。

  • Turning to full year 2026 P&L guidance. We are increasing both the reported and organic revenue outlook due primarily to the DSA and manufacturing outperformance in the second-quarter and our expectations for further improvements during the remainder of the year. We now expect reported revenue to decline in the range of 2.5% to 3.5%, driven by the impact of completed divestitures.

    接著談 2026 全年損益(P&L)指引。我們上調報告口徑與有機營收展望,主要因第二季 DSA 與製造業務表現優於預期,以及我們預期今年剩餘期間將進一步改善。我們目前預期報告口徑營收將下滑 2.5% 至 3.5%,主要受已完成的資產剝離影響所致。

  • We're also raising our organic revenue growth in the range of flat to a 1% increase, which represents a 150-basis point improvement to our prior guidance. By segment, on an organic basis, we're increasing our DSA revenue outlook to low single-digit growth for the year, and we're also adjusting our manufacturing revenue outlook higher to a low to mid-single-digit growth rate. Our RMS outlook remains unchanged.

    我們也將有機營收成長上調至持平至成長 1% 的區間,較先前指引改善 150 個基點。以事業部門來看,在有機基礎上,我們將 DSA 營收展望上調至全年低個位數成長,並將製造業務營收展望上調至低至中個位數成長率。我們對 RMS 的展望維持不變。

  • Moving to profitability. We continue to expect operating margin expansion of approximately 120 to 150 basis points in 2026, with the Manufacturing and DSA segments driving the year-over-year increase. We have a clear line of sight into the second half improvement of at least 500 basis points compared to the first half of the year.

    接著談獲利能力。我們仍預期 2026 年營業利益率將擴張約 120 至 150 個基點,其中製造與 DSA 事業部門將帶動年對年提升。我們對下半年相較上半年至少改善 500 個基點有清晰的能見度。

  • As shown on slide 14, approximately 50% of the second half improvement will be attributable to the portfolio actions already completed, including the full benefit of the divestitures as well as the lower NHP sourcing costs from the K.F. acquisition, which will largely benefit the fourth-quarter. Lower corporate costs are estimated to drive approximately 150 basis points of the improvement with the balance derived from other operational contributors, including efficiency savings.

    如投影片 14 所示,下半年改善幅度約有 50% 可歸因於已完成的投資組合行動,包括資產剝離的完整效益,以及因 K.F. 收購案帶來較低的 NHP 採購成本,該效益將主要反映在第四季。較低的公司層級成本預估將貢獻約 150 個基點的改善,其餘則來自其他營運面貢獻,包括效率節省。

  • Lower corporate costs in the second half will reflect favorable stock compensation expense related to the CEO transition and fringe costs, which are typically lower in the second half of the year. We are also increasing our non-GAAP earnings per share guidance to a range of $11.15 to $11.45, which represents 8% to 11% year-over-year growth and an increase of $0.25 at the midpoint of our prior outlook.

    下半年較低的公司層級成本將反映與 CEO 交接相關的股權薪酬費用有利因素,以及通常在下半年較低的附加福利成本。我們也將非 GAAP 每股盈餘指引上調至 11.15 至 11.45 美元區間,代表年對年成長 8% 至 11%,且相較先前展望的中點上調 0.25 美元。

  • The increase reflects the expected operational outperformance for the year, driven primarily by improving trends in the DSA segment and a better-than-expected performance in the Manufacturing segment. Separately, we expect the $0.19 net benefit associated with the deferred compensation plan will not have a meaningful impact on non-GAAP earnings per share in 2026 as it is expected to be entirely offset by the higher tax rate outlook for the year, which is an approximate $0.20 headwind.

    此上調反映我們預期全年營運表現將優於預期,主要由 DSA 事業部門趨勢改善,以及製造事業部門表現優於預期所帶動。另外,我們預期與遞延補償計畫相關的 0.19 美元淨利益在 2026 年不會對非 GAAP 每股盈餘造成實質影響,因其預期將被全年較高稅率展望完全抵銷;該較高稅率約造成每股 0.20 美元的不利影響。

  • For the third-quarter, revenue is expected to decline approximately 4% to 6% on a reported basis, primarily driven by the impact of the completed divestitures. We expect organic revenue growth of approximately 1% to 3% year-over-year, reflecting improving demand trends in the DSA segment and an expected rebound in Biologics Testing growth rate, which will drive higher manufacturing revenue growth.

    第三季方面,報告口徑營收預期將下滑約 4% 至 6%,主要受已完成資產剝離的影響所致。我們預期有機營收年對年成長約 1% 至 3%,反映 DSA 事業部門需求趨勢改善,以及生物製劑測試(Biologics Testing)成長率預期回升,將帶動製造業務營收成長提高。

  • In addition, operating margin is projected to improve approximately 200 basis points sequentially versus the second-quarter due largely to lower corporate costs and a full quarter benefit from the divestitures. For the third-quarter, we expect non-GAAP earnings per share in the range of $2.90 to $3.00, representing an approximate 20% year-over-year increase.

    此外,營業利益率預估將較第二季按季改善約 200 個基點,主要由較低的公司層級成本以及資產剝離帶來的完整季度效益所驅動。第三季我們預期非 GAAP 每股盈餘介於 2.90 至 3.00 美元,約為年對年增加 20%。

  • As previously mentioned, the higher tax rate outlook creates a $0.10 headwind to third-quarter earnings per share, which has been included in the guidance. In conclusion, I'm encouraged by the recent improvement in the underlying business trends and our first half performance, including the execution of our strategic priorities, which demonstrate our commitment to our pathway to purpose strategy and enhancing long-term shareholder value.

    如先前所提,較高的稅率展望將對第三季每股盈餘造成 0.10 美元的不利影響,且已納入本次指引。總結而言,我對近期基礎業務趨勢的改善以及我們上半年表現感到鼓舞,包括我們在策略優先事項上的執行,這些都展現我們對「Pathway to Purpose」策略以及提升長期股東價值的承諾。

  • Over the past several months, I've had the opportunity to meet with employees across our global organization as well as shareholders and other stakeholders. These interactions have further strengthened my confidence in our capabilities, our people and the momentum we are building across the organization. I look forward to continuing to work with the team to execute our strategy and to sharing more information about our long-term priorities and financial targets at our upcoming Investor Day on September 24. Thank you.

    在過去幾個月,我有機會與我們全球組織各地的員工,以及股東與其他利害關係人會面。這些互動進一步強化我對我們能力、人才以及我們在整個組織內所建立動能的信心。我期待持續與團隊合作以落實我們的策略,並在 9 月 24 日即將舉行的投資人日分享更多關於我們長期優先事項與財務目標的資訊。謝謝。

  • Todd Spencer - Corporate Vice President, Investor Relations

    Todd Spencer - Corporate Vice President, Investor Relations

  • That concludes our comments. We will now take your questions.

    以上為我們的說明。接下來我們將開始回答各位的提問。

  • Operator

    Operator

  • (Operator Instructions) Kallum Titchmarsh, Morgan Stanley.

    (接線員指示)Morgan Stanley 的 Kallum Titchmarsh。

  • Kallum Titchmarsh - Analyst

    Kallum Titchmarsh - Analyst

  • Wanted to start actually on AI. We've been fielding quite a lot of questions on the space in relation to kind of preclinical work, and you called out some of the partnerships here. So maybe just talk us through your expectations for the preclinical pipeline evolving from that smarter drug discovery and whether that seems like a plausible thesis to you based on the discussions you've had with customers.

    我想先從 AI 談起。我們在這個領域收到相當多與臨床前工作相關的問題,而你也提到了一些合作夥伴關係。所以也許請你談談,你對於更智慧的藥物發現所帶動的臨床前研發管線如何演進的預期,以及基於你與客戶的討論,這是否是你認為合理可行的論點。

  • I think we're just trying to work out when that impact starts creeping into numbers via more like IND-enabling studies, but would love your views there.

    我想我們也在試著釐清,這樣的影響何時會開始透過更像是 IND 申請前的關鍵研究(IND-enabling studies)逐步反映到數字上,也很想聽聽你的看法。

  • Birgit Girshick - Chief Executive Officer

    Birgit Girshick - Chief Executive Officer

  • Thanks, Kallum, and absolutely happy to. So obviously, AI is a hot topic everywhere. And we talk to a lot of clients about it, what their expectations is, where they're investing into. And so from our perspective, a lot of the articles or the pieces that were published support our thesis on it. So once AI provides more productivity into the molecule design, target identification, makes more molecules may be available to move into the validation stage and the regulated safety assessment stage and makes the molecule design more efficient, we expect more programs to work itself through the safety assessment stage, the validation stage, the area that is core to us. And we expect that it will actually be a tailwind for us and drive demand.

    謝謝你,Kallum,當然很樂意。很明顯地,AI 在各處都是熱門話題。我們也和許多客戶談到這件事:他們的預期是什麼、他們把投資放在哪裡。從我們的角度來看,許多已發表的文章或報導都支持我們的論點。因此,一旦 AI 提升分子設計與標的辨識的生產力,使更多分子能進入驗證階段與受規範的安全性評估階段,並讓分子設計更有效率,我們預期會有更多專案推進並通過安全性評估與驗證階段——這些領域正是我們的核心。我們預期這實際上將成為我們的順風因素,並帶動需求。

  • Timing is a little bit more difficult to estimate. Obviously, companies have worked on AI for a long time. But on the other hand, technology is accelerating -- so really, we'll have to see when those efficiencies are being delivered, when the cost savings for our clientele can materialize. What we are already seeing actually is that a lot of companies that are more AI native or drug discovery companies that use AI platforms, they're generally running more programs than a typical biotech that generally comes in with one or two programs.

    時點的掌握會比較難估計。顯然,企業在 AI 上已經投入很長一段時間。但另一方面,技術正在加速發展——因此,我們確實還得觀察這些效率何時能夠被交付、何時能讓我們客戶的成本節省真正實現。我們目前其實已經看到的是,許多更「AI 原生」的公司,或是使用 AI 平台的藥物發現公司,通常同時在跑的專案數量會比一般生技公司更多;一般生技公司通常只帶著一到兩個專案進來。

  • The numbers are still very small, but that will accelerate materially over the next, I would say, year or 2. So we should see some impact -- positive impact over the next few years, but it will take some time to really ramp that up. And when it's going to be material is a little bit harder to estimate. But I think you will see some ramp-up over the next couple of years, more programs, more validation, more data needed to validate the platforms.

    目前數字仍然很小,但我認為在接下來一到兩年會顯著加速。因此,未來幾年我們應該會看到一些影響——正面的影響,但要真正把規模拉上來仍需要一些時間。至於何時會變得「具實質性」則更難估計。但我認為接下來幾年你會看到一些爬坡:更多專案、更多驗證,以及需要更多數據來驗證這些平台。

  • So all of that should be a tailwind for the work we do. In addition to that, we, as a company, are investing in AI tools, enabling platforms that give us more insights, also allow us to put efficiencies in place. Those are all really focused on the work we do. So that validation, safety assessment stage that is core to us. And that will allow us to differentiate ourselves to help our clients to move faster, time is money as usual and then also provide us for our work with some efficiencies.

    因此,這些都應該會成為我們所做工作的順風。除此之外,我們公司也在投資 AI 工具與賦能平台,讓我們獲得更多洞見,同時也能導入效率提升。這些都非常聚焦在我們所做的工作上。也就是對我們而言核心的驗證與安全性評估階段。而這將使我們能夠形成差異化,協助客戶更快推進——一如既往,時間就是金錢——同時也為我們自身的工作帶來一些效率。

  • So we are really excited about AI. I think it will be an enabler, a differentiator. But obviously, technology has to advance and continue to advance and then prove itself. But great question, Kallum.

    所以我們對 AI 真的非常興奮。我認為它會是一個賦能者、也是差異化因素。但顯然,技術必須持續進步、繼續進步,並且證明其價值。不過問得很好,Kallum。

  • Kallum Titchmarsh - Analyst

    Kallum Titchmarsh - Analyst

  • Yes. That's great color. And then just secondly, when we think about the portfolio refinement we've seen over the past year or so, clearly, benefits starting to come through from that. Is it fair to assume you're now comfortable with the current shape of the business? Maybe just talk through appetite for maybe more deals or divestitures and then more broadly to capital allocation.

    是的。這些補充很有幫助。第二個問題是,當我們回顧過去一年左右看到的投資組合精煉(portfolio refinement),顯然其效益開始顯現。是否可以合理地假設,你們現在對目前業務的樣貌已經感到滿意?也請談談你們對於可能進一步交易或剝離(divestitures)的意願,以及更廣泛的資本配置(capital allocation)。

  • Birgit Girshick - Chief Executive Officer

    Birgit Girshick - Chief Executive Officer

  • Yes. I'm going to start on that, and then I'll let Glenn chime in here a little bit more on the capital allocation. So from a point of divestitures, we absolutely are seeing the benefits from that, both financially in terms of our OI improvements, but also from an ability to focus on the core portfolio. So -- and that was a big driver for us to really getting back to core to what we do best, where we have the biggest relevance to our clients, where we provide the highest value.

    是的。我先回答這部分,接著我會請 Glenn 再補充一些關於資本配置的看法。就剝離而言,我們確實看到了其帶來的效益:財務面上,例如我們營業利益(OI)的改善;同時也提升了我們聚焦核心投資組合的能力。因此——這也是推動我們回到核心、回到我們最擅長的事情的一大動因:在那裡我們對客戶最具相關性、也能提供最高價值。

  • And that will allow us as a leadership team, but also our sales organization and our operational organization to really focus on being the best partner for our clients possible. We continue to look at our portfolio like we always have done. So if you think back, Charles River has, over the years, divested other businesses. We have had a program of site consolidations, but we also have a healthy appetite for M&A.

    這也讓我們的領導團隊、以及我們的銷售組織與營運組織,能夠真正專注於成為客戶最好的合作夥伴。我們會一如既往地持續檢視我們的投資組合。回顧過去,Charles River 多年來也曾剝離其他業務。我們也推動過據點整併計畫,但同時我們對併購(M&A)也有健康的胃納。

  • So we will continue to look at all of that. Nothing imminent on the divestitures. We're still continuing to execute on some site closures that we had announced last year. And certainly, from an M&A perspective, we have a good road map. We have a clear target area we are interested in. But as you know, it's always difficult to estimate when targets are available, are they coming in for the right price. So more to be seen. But definitely, we will keep it broad-based and continue to look at refining our portfolio.

    因此,我們會持續評估所有這些選項。目前沒有任何迫在眉睫的剝離事項。我們仍在持續執行去年宣布的一些據點關閉計畫。而就併購角度而言,我們有一個不錯的路線圖。我們也有明確感興趣的目標領域。但如你所知,目標何時可得、以及是否能以合適的價格成交,永遠都很難估計。所以還有待觀察。但可以確定的是,我們會保持廣泛的視角,並持續精煉我們的投資組合。

  • Glenn Coleman - Chief Financial Officer, Executive Vice President

    Glenn Coleman - Chief Financial Officer, Executive Vice President

  • Yes. And the only thing I'd add is, obviously, our balance sheet is in very good shape. We can support our acquisition strategy going forward. If you look at where our leverage is, we ended around 2.5 times even after the most recent $100 million share repurchase that we did in the second-quarter. We generated strong cash flows in the quarter. We actually raised our free cash flow guidance.

    是的。我唯一想補充的是,顯然我們的資產負債表狀況非常好。我們有能力支持未來的收購策略。如果看我們的槓桿水準,即便在第二季完成最近一次 1 億美元的庫藏股回購之後,我們期末槓桿大約仍在 2.5 倍左右。我們在本季產生了強勁的現金流。我們其實也上調了自由現金流指引。

  • We have plenty of capacity under our existing revolver at very attractive rates. And so I think we're very well positioned from a balance sheet perspective to support our acquisition strategy. You can never predict when they're going to happen, but we'd love to be able to add a couple of additional companies to our portfolio.

    在現有循環信貸(revolver)之下,我們仍有充足的可用額度,而且利率條件非常具吸引力。因此,我認為從資產負債表角度來看,我們非常有利於支持收購策略。你永遠無法預測交易何時會發生,但我們很希望能再把一兩家額外的公司納入我們的投資組合。

  • Operator

    Operator

  • Ann Hynes, Mizuho.

    Ann Hynes,瑞穗(Mizuho)。

  • Ann Hynes - Analyst

    Ann Hynes - Analyst

  • Great. On the call, you talked about how the demand in biotech was accelerating. Can you talk about your other customer segments, especially how large biopharma is doing?

    很好。在電話會議上,你提到生技領域的需求正在加速。你能談談其他客戶區隔嗎,特別是大型生物製藥(large biopharma)的表現如何?

  • Birgit Girshick - Chief Executive Officer

    Birgit Girshick - Chief Executive Officer

  • Yes, happy to, Ann. So it's actually great to see that both our major client segments are strengthening, and we're seeing more demand from both of them and our KPI -- forward-looking demand KPIs are strengthening in both segments. Looking at the global biopharma specifically -- most or all of our global biopharma clients, and we work with all of them, have moved through their portfolio prioritization, have moved through their restructurings over the last few years.

    可以的,Ann,很樂意。其實很高興看到我們兩大主要客戶區隔都在轉強,我們從兩邊都看到更多需求,而且我們的 KPI——前瞻性的需求 KPI——在兩個區隔都在改善。就全球生物製藥(global biopharma)來看——我們的大多數或全部全球生物製藥客戶(而且我們與他們全部都有合作)在過去幾年已經完成其投資組合優先順序調整,也走過了重整階段。

  • And over the last 18 months, we've really seen them coming back to work, booking more work, more discussions, more proposals and fewer cancellations. So it's going all in the right direction. And we have a lot of discussions with those clients. So we understand that their focus right now is on more molecules into the clinic, more molecules approved and being approved for commercial distribution to the patients.

    而在過去 18 個月,我們確實看到他們回到工作節奏:承接更多工作、更多討論、更多提案,且取消案更少。所以整體都朝正確方向發展。我們也與這些客戶有大量交流。因此我們了解,他們目前的重點是讓更多分子進入臨床、讓更多分子獲批,並獲批後用於商業化供應給病患。

  • So it's all about more programs, more speed, more agility, and I think we are the differentiated partner for them to help them execute on that.

    所以核心就是更多專案、更快速度、更高敏捷性;我認為我們是他們具差異化的合作夥伴,能協助他們把這些落實執行。

  • Ann Hynes - Analyst

    Ann Hynes - Analyst

  • Great. And my follow-up question is just about China. I get asked a lot about this. And I think there's like two competitive debates investors are focused on. One is just like the increasing capability of Chinese CROs and the other is whether a large pharma is bringing more preclinical work in-house in China. Maybe can you talk about these as real risks and how do you think about it long term?

    很好。我的追問是關於中國。我常常被問到這個問題。我認為投資人主要聚焦在兩個競爭面的討論。第一是中國 CRO 能力的提升;第二是大型藥廠是否在中國把更多臨床前工作內製(in-house)。你能談談這些是否為真實風險,以及你們長期如何看待嗎?

  • Birgit Girshick - Chief Executive Officer

    Birgit Girshick - Chief Executive Officer

  • Yes. And so we certainly watch China very, very, very closely, right? So an emerging or maybe a little bit past emerging innovative market, really interesting from a perspective of serving this market directly. As you know, we have a strong research models and services business in China. So we are a well-established, highly respected participant in that industry.

    是的。因此我們當然非常、非常、非常密切地關注中國,對吧?這是一個正在崛起、或許已經略過「新興」階段的創新市場;從直接服務該市場的角度來看非常有意思。如你所知,我們在中國擁有強勁的研究模型與服務業務。因此,我們是該產業中根基深厚、備受尊敬的參與者。

  • And it certainly would serve well to expand on that business. And so we're looking at options at any given time at how we can accomplish that. From the other hand is the -- as you said, the competition in China, adding more capabilities. This is a trend that has started probably a decade, maybe even longer, really focused initially on the very early-stage capabilities, chemistry and biology.

    而這當然也將有助於擴展那項業務。因此,我們在任何時點都在評估有哪些選項可以達成這一點。另一方面則是——如你所說——中國的競爭者正在增加更多能力。這是一個大概在十年前、甚至更久以前就開始的趨勢,最初主要聚焦在非常早期階段的能力,也就是化學與生物學。

  • And that market definitely has structurally changed and moved into a lower -- generally moved into a lower-cost countries, including China, but also a bit in India. We are now looking to see what their ability of bringing on more regulated work is -- this is still the minority generally focused on companies that are doing their Phase I work in China, but we are watching that very closely and are very prepared to differentiate ourselves here in the West with our services, with our speed, with our supply chain and being the best partner we can be here for our clients.

    而那個市場的結構確實已經改變,並且轉移到成本較低的國家——整體而言轉向較低成本的國家,包括中國,也有一部分在印度。我們現在在觀察他們承接更多受監管工作的能力如何——這目前仍屬少數,通常集中在那些在中國進行第一期(Phase I)工作的公司,但我們正非常密切地關注,並且也已準備好在西方以我們的服務、速度、供應鏈來做出差異化,成為客戶在這裡能找到的最佳合作夥伴。

  • Yes, some of our global biopharma clients are moving maybe more into China with some R&D centers. They do establish with that some capabilities. There, again, from what I can see at the very early stage, not so much in the regulated Safety Assessment market. I think all our global biopharma clients have established the understanding that it's really hard to be in this area, particularly because of that regulated nature, keeping up the scale and a capability that would make sense for them. So we believe that their investments are in the true R of the R&D stage and that we continue to support them in more of the development stage.

    是的,我們一些全球生物製藥客戶可能正把更多研發中心移到中國。他們也因此建立了一些能力。不過同樣地,從我在非常早期階段所看到的情況來看,在受監管的安全性評估市場方面並不多。我認為我們所有全球生物製藥客戶都已理解,這個領域真的很難做,特別是因為其受監管的特性,要維持規模與一套對他們而言合理的能力並不容易。因此我們相信,他們的投資是在研發階段中真正的「研」(R&D 裡的 R),而我們會持續在較偏開發階段支持他們。

  • Operator

    Operator

  • David Windley, Jefferies.

    David Windley,Jefferies。

  • David Windley - Equity Analyst

    David Windley - Equity Analyst

  • I'll forewarn you. This is a multiparter period. I'm interested in demand environment. You talked in the prepared remarks about pretty balanced demand in DSA across study types. I'm hearing that large molecule or large animal NHP specifically studies are in quite high demand to the point that maybe some of your competitors are running short on capacity in the near term.

    我先提醒一下。這會是一個多段式的提問。我關心的是需求環境。你們在事先準備的講稿中提到,DSA 在各種研究類型之間的需求相當均衡。我聽到的是,大分子或大型動物、特別是非人靈長類(NHP)研究的需求非常高,以至於你們的一些競爭對手在短期內可能會出現產能不足。

  • So my questions are what your view is of kind of the demand landscape by study type? And then help us to understand maybe a little bit more clearly the availability of NHPs that you have from previous Noveprim and more recently, K.F. -- and kind of how much excess capacity or animal supply can you dip into there? Or do you have to wait for contracts to run out? Are they already claimed et cetera, to be able to service what I think is NHP growing demand?

    所以我的問題是:你們如何看待按研究類型劃分的需求版圖?另外也請你們更清楚地說明一下,你們從先前的 Noveprim 以及較近期的 K.F. 所取得的 NHP 供應可用性——你們那邊大概有多少多餘產能或動物供應可以動用?還是你們必須等合約到期?它們是否已經被預訂等等,才能滿足我認為正在成長的 NHP 需求?

  • Birgit Girshick - Chief Executive Officer

    Birgit Girshick - Chief Executive Officer

  • Certainly, David. Great questions, and I wouldn't expect anything less than a multi question from you.

    當然可以,David。很好的問題,而且我也不會期待你只問一個問題。

  • David Windley - Equity Analyst

    David Windley - Equity Analyst

  • I got another one for you.

    我還有一個要問你。

  • Birgit Girshick - Chief Executive Officer

    Birgit Girshick - Chief Executive Officer

  • So looking at demand, yes, we talked about broad-based. We were referring quite a bit to pre-IND versus post-IND studies, which really has balanced out quite a bit, which is great because we need both. We need the pre-IND because that will eventually translate into post-IND. We also referred to healthy demand in the more complex areas and in NHP studies specifically.

    就需求來看,是的,我們談到的是廣泛的需求。我們相當多是在指 pre-IND 與 post-IND 研究之間的需求,而這兩者已經變得相當平衡,這很好,因為兩者我們都需要。我們需要 pre-IND,因為它最終會轉化為 post-IND。我們也提到在更複雜領域以及特別是 NHP 研究方面,需求相當健康。

  • And we believe that this is both very positive. It shows that clients are reinvesting in early-stage pre-IND work, but it also shows that clients are very focused on more complex modalities, which provides us with a nice uptick in revenue opportunity, both not only in the in vivo study, but also from a bioanalysis study because there's more revenue associated with a more complex modality than in small molecules.

    我們認為這兩者都非常正面。這顯示客戶正在重新投入早期的 pre-IND 工作,同時也顯示客戶非常聚焦於更複雜的治療模式(modalities),這為我們帶來不錯的營收機會上升,不僅是在體內(in vivo)研究上,也包括生物分析(bioanalysis)研究,因為相較於小分子,更複雜的治療模式所對應的營收更高。

  • Specific to your question on nonhuman primate supply, you obviously know and you referred to it that we have acquired a Mauritius farm a few years ago and then the Cambodian farm last year -- by having ownership of it, there's a couple of things that we can do that we would otherwise not be able to do. Number one is control the quality, the logistics, the timing of shipments, and that is helping us a lot.

    針對你關於非人靈長類供應的問題,你很清楚也提到了:我們在幾年前收購了模里西斯的一座農場,並在去年收購了柬埔寨的農場——透過擁有它們,我們可以做幾件原本做不到的事。第一是控制品質、物流與出貨時點,這對我們幫助很大。

  • But then also to control the capacity itself. So we can obviously breed more that will take a little bit of time, but we can also either accelerate some shipments or hold back some shipments. So it is really about managing the capacity to the peak levels. We still have third-party contracts that we were executing on. They are ramping down, and we will work through that with our customer over the next few years and move more and more of those animals into client studies in our DSA segment.

    另外也能控制產能本身。因此我們當然可以增加繁殖量——這需要一些時間——但我們也可以加速某些出貨或延後某些出貨。所以重點在於把產能管理到尖峰水位。我們仍有一些第三方合約正在執行。這些合約正在逐步下降,我們會在未來幾年與客戶一起處理,並把越來越多的動物轉入我們 DSA 部門的客戶研究中。

  • So overall, we are quite happy that we are integrated into the supply chain, as you can imagine. We are in a very healthy state of having animals available. We'll have to see where demand goes. We are really differentiated now because of that nonhuman primate supply. And we see that as a possibility, obviously, to gain market share. But overall, I think we're in the best state possible at this stage, and we will leverage that.

    總體而言,如你所想像的,我們很高興能整合進供應鏈。我們目前在動物可用性方面處於非常健康的狀態。接下來就要看需求走向。我們現在因為非人靈長類供應而具備明顯差異化。我們也把這視為一個機會,顯然可以用來提升市占率。但整體來說,我認為在這個階段我們已處於最佳狀態,並且會善用這一點。

  • David Windley - Equity Analyst

    David Windley - Equity Analyst

  • Great. If I could just squeeze in a follow-up quickly on the same topic. I think as I'm looking at both consensus and our numbers relative to the guidance that you're giving for third-quarter, I think the primary difference is kind of a cadence of perhaps your access or the benefit of the NHP cost drop to your margin. It sounds like it's landing mostly in the fourth-quarter rather than the third-quarter.

    很好。如果可以的話,我想就同一主題快速追問一下。我在看市場共識與我們的數字、相對於你們給出的第三季指引時,我認為主要差異在於節奏(cadence),也就是你們取得 NHP 成本下降所帶來的利益、反映到毛利率上的時間點。聽起來它主要落在第四季,而不是第三季。

  • Maybe I don't know if this is a Glenn question, but maybe you could talk a little bit about the cadence. Are there animals that are going to be on quarantine in the third-quarter that are depressing that impact a little bit, just kind of the third-quarter, fourth-quarter cadence as to how that KF benefit materializes.

    也許我不確定這是不是 Glenn 的問題,但也許你們可以談談這個節奏。第三季是否會有動物處於隔離檢疫期,因而讓影響稍微被壓低?也就是第三季、第四季之間的節奏,K.F. 的效益是如何實現的。

  • Glenn Coleman - Chief Financial Officer, Executive Vice President

    Glenn Coleman - Chief Financial Officer, Executive Vice President

  • Yes. No. So, relative to the margins and what we see right now, we're expecting a minimal impact in Q3. There will be some impact, but very small. The large impact will be in Q4. And so we do expect to see a very meaningful move in margins in DSA in the fourth-quarter as a result of the NHPs and then being placed on studies and those direct costs going lower in Q4. And that's where we're going to see the biggest impact.

    是的。不。所以,就毛利率以及我們目前所看到的情況而言,我們預期第三季的影響很小。會有一些影響,但非常有限。較大的影響會在第四季。因此,我們確實預期第四季 DSA 的毛利率會出現非常顯著的改善,原因是 NHP 會被安排進研究中,而這些直接成本在第四季會下降。這就是我們會看到最大影響的地方。

  • Birgit Girshick - Chief Executive Officer

    Birgit Girshick - Chief Executive Officer

  • Yes. And David, you got it absolutely right. So, just thinking through, you understand the timing of importation, quarantine, getting them on study and then generating revenue. It just takes some time to import them, quarantine them, acclimate them and then get them on study and generate revenue. It's just a matter of timing.

    是的。而且 David,你完全說對了。所以,稍微推演一下,你理解進口的時點、隔離檢疫、讓牠們進入研究,然後才開始產生營收的時間安排。進口、隔離檢疫、適應環境,接著再安排進研究並產生營收,都需要一些時間。這就是時間點的問題。

  • Operator

    Operator

  • Charles Rhyee, TD Cowen.

    Charles Rhyee,TD Cowen。

  • Charles Rhyee - Analyst

    Charles Rhyee - Analyst

  • Just wanted to follow up maybe a little bit more on that -- on David's cadence question here. So if I think, Glenn, you said that 4Q DSA revenue will be the highest. And I guess the question then is, is that the right kind of run rate we should think about as we look forward into '27? Because clearly, when we've seen the strong demand uptick and we're seeing this continuous improvement in the book-to-bill, is maybe then the 4Q the right jump-off point? Or is there anything that maybe because it's maybe delayed from 3Q to 4Q that might be sort of a onetime-ish kind of benefit partially so that we shouldn't use that as the jump-off point?

    我想就剛才那點再追問一下——關於 David 在這裡提到的節奏問題。所以如果我理解沒錯,Glenn,你說第四季(4Q)的 DSA 營收會是最高。那我想問的是,當我們展望到 2027 年時,這是否就是我們應該用來思考的合理「運行水準」(run rate)?因為很明顯地,當我們看到需求強勁回升、且訂單出貨比(book-to-bill)持續改善時,第四季是否就是正確的起跳點?還是說,有沒有任何因素可能因為從第三季(3Q)延後到第四季(4Q),而帶來某種一次性(onetime-ish)的部分利多,因此我們不應該把它當作起跳點?

  • Glenn Coleman - Chief Financial Officer, Executive Vice President

    Glenn Coleman - Chief Financial Officer, Executive Vice President

  • Yes. Charles, let me give you a little color. So, your comment on revenues, my comment was really around margin being the highest for DSA in the fourth-quarter, to be clear. and that's driven by these lower costs for the NHPs. As we look at the sequencing of margins, I mentioned in my prepared remarks about a 200-basis point sequential improvement from Q2 to Q3.

    是的。Charles,我補充一些背景說明。關於你提到的營收,我先前的評論其實是針對 DSA 在第四季的毛利率會是最高,先澄清一下。這主要是由於 NHP 的成本較低所帶動。至於毛利率的時序變化,我在事先準備的發言中提到,從第二季(Q2)到第三季(Q3)毛利率將有 200 個基點的季增改善。

  • That's largely driven by lower corporate costs and some benefit from divestitures. And then we'd expect probably about another 300-basis point improvement to Q4 to get to our full year guidance numbers, and most of that will come from the acquisition of KF Cambodia and the benefit we'll see in the DSA segment. So just so you know how we're sequencing out the Q3 and Q4 margins and obviously, the comments that I made earlier around the margins, not the revenue.

    這主要是由於公司層級成本降低,以及部分來自資產剝離(divestitures)的效益。接著我們預期到第四季(Q4)大概還會再改善約 300 個基點,以達到我們全年指引的數字,而其中大部分將來自收購 KF Cambodia,以及我們在 DSA 部門將看到的效益。所以讓你了解我們如何安排第三季與第四季的毛利率走勢;而且我先前的評論顯然是針對毛利率,不是營收。

  • Charles Rhyee - Analyst

    Charles Rhyee - Analyst

  • Okay. That's helpful. Sorry, I must have misheard. And then maybe just a quick follow-up on the tax rate change. You said part of it is due to a proposed tax legislation change. Do we know when that will actually be finalized? Or -- so is this an estimation of a posed change? And is there a chance that maybe it doesn't go through?

    了解。這很有幫助。抱歉,我可能聽錯了。另外再快速追問一下稅率變動。你提到其中一部分是因為一項擬議中的稅務立法變更。我們知道它實際上何時會定案嗎?或者——所以這是對擬議變更的估計嗎?那是否有可能最後不會通過?

  • Glenn Coleman - Chief Financial Officer, Executive Vice President

    Glenn Coleman - Chief Financial Officer, Executive Vice President

  • Thanks for the question. So, this is associated with Mauritius, and we are expecting to hear back literally any day now on what the changes are going to be. We've obviously been in close contact with the local authorities and understanding what this could be. And so we've modeled in our guidance the impact we are expecting. If for some reason, the impact is less, it would obviously be upside to our guidance right now.

    謝謝你的問題。這與模里西斯(Mauritius)相關,我們預期 буквально 任何一天就會收到回覆,了解變更內容會是什麼。我們當然一直與當地主管機關保持密切聯繫,並了解可能的變化。因此我們已在指引中納入我們預期的影響。如果因為某些原因影響較小,那顯然會成為我們目前指引的上行因素。

  • And just to put a finer point on it, when we raised our EPS guidance for the year by $0.25 at the midpoint, that's all operational. We have about a $0.19 gain overall that we expect to flow through the year, but we're anticipating a $0.20 tax headwind to offset that. So if for some reason, this tax legislation change does not happen, there would be upside to our EPS numbers. But right now, from what we know, we're pretty comfortable that it's going to happen, and we've factored it into our guidance.

    再更精確地說,當我們把全年 EPS 指引在中位數上調 0.25 美元時,那完全是營運面的提升。我們預期全年合計約有 0.19 美元的收益會反映進來,但我們也預期會有 0.20 美元的稅務逆風來抵銷。所以如果因為某些原因這項稅務立法變更沒有發生,我們的 EPS 數字就會有上行空間。但就我們目前所知,我們相當有把握它會發生,因此已將其納入指引。

  • Operator

    Operator

  • Michael Ryskin, Bank of America.

    Michael Ryskin,美國銀行(Bank of America)。

  • Michael Ryskin - Analyst

    Michael Ryskin - Analyst

  • Congrats on a great quarter. Birgit, maybe kind of going back to some of your prepared remarks on DSA strength, the book-to-bill commentary. You talked about demand trends, both in biotech and pharma. I would love to hear you talk -- comment on what you view as your capacity to support this. As you talked about, there's a lag between when some of these things convert into -- when funding converts into bookings, bookings convert into revenue. You've kind of tweaked capacity in DSA in prior years.

    恭喜本季表現非常出色。Birgit,我想回到你在事先準備發言中提到的 DSA 強勁表現與訂單出貨比(book-to-bill)的評論。你談到生技與製藥兩端的需求趨勢。我很想聽你談談——你如何看待你們支援這些需求的產能能力。如你所說,從資金到訂單、訂單到營收之間存在時間落差。你們過去幾年也曾在 DSA 調整過產能。

  • Just talk about where you feel like you are now in terms of ability to absorb as that funding starts to flow through or if there's incremental investments you need to make. So like where are you looking out 12, 18, 24 months on that front?

    請談談你們目前在吸收這些需求方面的能力——當資金開始逐步反映出來時,或是你們是否需要進一步增加投資。也就是說,在這方面你們對未來 12、18、24 個月的觀察重點是什麼?

  • Birgit Girshick - Chief Executive Officer

    Birgit Girshick - Chief Executive Officer

  • Yes. Thanks for the question, Mike. So, because of some volume declines over the last few years, we have sufficient capacity for a while. Obviously, it depends on the growth rate and the volume growth rate as such. But at this stage, we don't see any issues neither from an in vivo perspective, so animal rooms, equipment and then we will have to make some adjustments in people, but that isn't always, always.

    是的。謝謝你的問題,Mike。由於過去幾年量能有所下滑,我們在一段時間內都有足夠的產能。當然,這取決於成長率以及量能成長率本身。但就目前而言,無論是從 in vivo 的角度——例如動物房、設備——我們都看不到任何問題;在人力方面我們可能需要做一些調整,但那並不是一直、一直都需要。

  • So that is just part of doing business. From a lab perspective, we actually have expansions in progress. They are geared towards the future demand. And currently, we are fine, but we will need to execute on those expansions over the next couple of years. to be able to grow with the market or above. So overall, quite comfortable with what we have on capacity. Utilization will improve a little bit, which is a good thing. And -- but we don't see a bottleneck there.

    這只是經營業務的一部分。從實驗室的角度來看,我們其實正在進行擴建。這些擴建是為了未來需求所做的配置。目前我們沒有問題,但未來幾年我們需要把這些擴建執行到位,才能跟著市場一起成長,甚至高於市場成長。整體而言,我們對現有產能相當有信心。產能利用率會小幅提升,這是好事。但我們不認為那裡會出現瓶頸。

  • Michael Ryskin - Analyst

    Michael Ryskin - Analyst

  • Okay. And maybe a quick follow-up on pricing, both on NHPs and just more broadly, what you see in 2Q, what are your expectations for the second half? How is that kind of playing out with the uptick in demand?

    了解。另外快速追問一下定價,包含 NHP 以及更廣泛的定價:就第二季(2Q)你們看到的情況,以及你們對下半年有什麼預期?在需求回升的情況下,定價的走勢是如何發展的?

  • Birgit Girshick - Chief Executive Officer

    Birgit Girshick - Chief Executive Officer

  • Yes. Happy to address that, too. So, obviously, what we're seeing in Q2 right now is mostly booked a few quarters ago. And so, that -- what's flowing through right now is proposals that were basically done last year. But overall, what I would say is pricing has not materially improved yet. So, pricing is still stable. It is at the levels that we have seen for the last few years. Not more discounting, not less discounting.

    是的。我也很樂意回應。很明顯地,我們現在在第二季看到的,多數是在幾個季度前就已經簽下(booked)的。因此,目前反映出來的是基本上去年就完成的提案。但整體而言,我會說定價目前還沒有實質改善。所以,定價仍然穩定。它維持在我們過去幾年看到的水準。沒有更多折扣,也沒有更少折扣。

  • We are aggressive going after work, which shows in our capture rates. I'm actually quite happy seeing a little bit of an uptick in our capture rates, which indicates that our approaches -- our go-to-market approach is working. Our pricing strategies are working and that our differentiation strategy is working. And -- but we are looking kind of forward to the time where pricing becomes a little bit more available.

    我們積極爭取業務,這也反映在我們的得標率(capture rates)上。我其實很高興看到我們的得標率有些微上升,這表示我們的方法——我們的市場進入策略(go-to-market approach)正在奏效。我們的定價策略正在奏效,也表示我們的差異化策略正在奏效。不過,我們也在期待未來某個時間點,定價能變得更有空間一些。

  • We do think that will happen with capacity filling up a bit more over the next few quarters. But then again, it will take some time to work through that in our backlog. So just as a reminder, if we get a proposal today, it generally takes a quarter to go into bookings, another quarter or two to go into revenue generation. So any pricing uptick we might see in the upcoming quarters would flow through then in 2027, not before. So -- but I think pricing will improve as capacity improves.

    我們確實認為,隨著未來幾個季度產能逐步被填滿,這種情況會發生。但同樣地,這需要一些時間才能在我們的在手訂單(backlog)中消化反映。提醒一下,如果我們今天拿到一份提案,通常需要一個季度才會轉成訂單(bookings),再需要一到兩個季度才會轉為營收。因此,我們在接下來幾個季度可能看到的任何定價上行,會在 2027 年才會反映出來,不會更早。不過,我認為隨著產能狀況改善,定價也會改善。

  • Operator

    Operator

  • Justin Bowers, Deutsche Bank.

    Justin Bowers,德意志銀行。

  • Justin Bowers - Analyst

    Justin Bowers - Analyst

  • Just going back to an earlier question on China. I was going to take it in a different direction. But on the clinical side, we're starting to see some of the in-licensing flow back in the US And given the demand profile over there and what we think is some upward pressure on price over there, are you starting to see an uptick in work from biotechs that might have otherwise gone over there, stay here or that's coming back here? Can you talk about the opportunity set there? And then on pricing, are you starting to see that approach parity around the DSA side?

    我想回到先前關於中國的一個問題。我原本打算從不同的角度切入。但在臨床端,我們開始看到一些授權引進(in-licensing)的流向回到美國。而且考量到那邊的需求輪廓,以及我們認為那邊價格可能面臨一些上行壓力,你們是否開始看到來自生技公司的工作量回升——也就是原本可能會去那邊做的,現在留在這裡或回流到這裡?能否談談那裡的機會集合?另外在定價方面,你們是否開始看到在 DSA 端的定價趨近於同等水準(parity)?

  • Birgit Girshick - Chief Executive Officer

    Birgit Girshick - Chief Executive Officer

  • Yes. So on the -- first -- your first question first. So on the biotechs that did work in China, most of those -- that work is in the early stage in the chemistry biology. We don't really do that work anymore. It was actually part of the business that we divested, and we divested that because it didn't quite have the synergies nor the benefits to our portfolio that we were looking for.

    是的。先回答——第一個——先回答你的第一個問題。就那些在中國做業務的生技公司而言,多數——那些工作是在早期階段的化學與生物領域。我們現在其實不太做那類工作了。那其實是我們已經剝離的業務之一;我們之所以剝離,是因為它與我們所尋求的投資組合協同效應與效益並不完全契合。

  • So for us, the regulated work that we are really focusing on our core business where most of our work is, has had very little influx into China so far. So not seeing this coming back doesn't mean the early stage isn't coming back. So basically, I can't really answer that question if the early-stage work is coming back because we're not seeing that in our proposals. It's not work we're doing.

    因此對我們而言,我們真正聚焦的核心業務——也就是我們大部分工作所在的受監管業務——到目前為止流入中國的比例非常少。所以我們沒有看到這些工作回流,並不代表早期階段的工作沒有回流。基本上,我無法真正回答早期階段工作是否正在回流,因為我們在提案中沒有看到那類需求。那不是我們在做的工作。

  • However, from discussions with clients, there is a level of uncertainty, but a bit more of a wait-and-see approach. And with the early stage work with the chemistry work because that goes relatively quickly, I think people will continue to work there until they can't anymore. So I don't think there is a huge need to build capacity here for them or move their work quickly.

    不過,從與客戶的討論來看,確實存在一定程度的不確定性,但更多是一種觀望(wait-and-see)的態度。而早期階段的工作、尤其是化學相關工作,因為週期相對快,我認為大家會繼續在那邊做,直到他們再也無法那樣做為止。所以我不認為他們有很大的需求要在這裡建立產能,或是快速把工作移回來。

  • So -- but certainly, discussions are very frequent about what's the future there? Should we bring work over there? Should we bring it back? But I don't think that particular biotech clients really have acted on that in a major fashion yet. From a pricing perspective, so what we are hearing is from some of our clients is that the companies that are doing work for the West.

    所以——但當然,大家非常頻繁地在討論那邊的未來會如何。我們是否應該把工作帶到那邊?是否應該把它帶回來?但我不認為那些特定的生技客戶到目前為止已經在重大程度上採取行動。從定價角度來看,我們從部分客戶那裡聽到的是,那些為西方市場提供服務的公司。

  • So there's a very specific group of CROs -- their pricing is not too far off anymore to the Western pricing. They're still lower. They will continue to be lower, and they need to be lower to actually have an attractiveness to work being done in the West because there's still complexity with language and time zones and other reasons. But it is moderating a little bit. Now pricing for Chinese biotech and pharma is still considerably lower. So I don't know if that answered your question, Justin.

    也就是有一個非常特定的 CRO 群體——他們的定價現在與西方定價已經相差不遠了。仍然比較低。而且他們會繼續維持較低,並且必須較低,才能讓把工作交由他們為西方市場執行仍具吸引力,因為語言、時區等因素以及其他原因仍然帶來複雜性。但確實正在稍微趨於緩和。不過,針對中國本土生技與製藥公司的定價仍然顯著偏低。所以我不確定這是否回答了你的問題,Justin。

  • Justin Bowers - Analyst

    Justin Bowers - Analyst

  • It does, Birgit. That's helpful.

    有的,Birgit。這很有幫助。

  • Operator

    Operator

  • Casey Woodring, JPMorgan.

    Casey Woodring,摩根大通。

  • Casey Woodring - Analyst

    Casey Woodring - Analyst

  • I just want to go back to the competitive comments you made about NHP-related safety assessment studies becoming a competitive advantage for you because you have security of supply. Can you maybe just elaborate on that a little bit? You've always sort of been the leader in this space, right? I think historically, you've owned at least 1/3 of the Safety Assessment market.

    我想回到你先前提到的競爭面評論:與 NHP(非人靈長類)相關的安全性評估研究,因為你們具備供應保障而成為你們的競爭優勢。你能否再多闡述一下?你們一直以來算是這個領域的領導者,對吧?我想從歷史上看,你們至少擁有安全性評估市場約 1/3 的份額。

  • So just curious how much your win rate has maybe increased as a result of more of this in-sourcing? And then how much higher you think your share could go here in the near term?

    所以我想了解的是,因為更多這類內部化(in-sourcing),你們的得標率(win rate)大概提升了多少?另外,你認為短期內你們的市占率還能提高到多高?

  • Birgit Girshick - Chief Executive Officer

    Birgit Girshick - Chief Executive Officer

  • Yes, I'm happy to. And Casey, so share is really hard to estimate. So I want to be very careful with that because there's really no public figures and many of our competitors are private companies, and we don't necessarily have the insight. So what we are looking at internally to see if our pricing strategies and our differentiation strategies are working is capture rate.

    好的,我很樂意。Casey,市占率其實很難估算。所以我必須非常謹慎,因為沒有公開數據,而且我們許多競爭對手是私人公司,我們不一定掌握相關洞見。因此,我們內部用來觀察我們的定價策略與差異化策略是否奏效的指標,是「捕獲率」(capture rate)。

  • And we had a nice uptick in our capture rate over the last few months. I wouldn't call it yet a trend because I want to see this trend continue for not just a quarter or two, but for the remainder of this year into next year, but still good to see. And I think it does show that we are focusing on the right things. In terms of differentiation and competitiveness from nonhuman primates, obviously, that's been always a risk area for the industry. Do we have enough nonhuman primates?

    過去幾個月,我們的捕獲率有不錯的上升。我還不會稱之為趨勢,因為我希望看到這個趨勢不只是延續一兩個季度,而是能在今年剩餘時間一路延續到明年;但看到這樣的表現仍然令人鼓舞。我認為這也顯示我們聚焦在正確的事情上。就非人靈長類帶來的差異化與競爭力而言,顯然這一直是產業的風險領域。我們是否有足夠的非人靈長類?

  • Do we have them at the time when we need them by being in control of that supply chain in control of the timing, when we bring them in, quarantine them, when we can put them on studies, -- that really gives our clients a lot of assurance that they can run their studies when they need them and that they don't have a time delay. So -- and I think that is a big benefit that we're bringing to the marketplace. And I think it's very acknowledged by our clients and just is deepening our client relationships and our preferred partnerships.

    我們是否能在需要的時間點取得它們——透過掌控該供應鏈、掌控時程,包括何時引進、隔離檢疫,以及何時能安排進入研究——這確實能讓客戶更有把握,他們能在需要時啟動研究且不會出現時間延誤。所以——我認為這是我們帶給市場的一項重大效益。而且我認為客戶非常認可這一點,並且正加深我們的客戶關係與優先合作夥伴關係。

  • Casey Woodring - Analyst

    Casey Woodring - Analyst

  • Got it. That's helpful. And then maybe just one quickly on RMS. You mentioned academic and government is still weak. We've heard sort of mixed signals from some of the tools vendors on that end market. So maybe just talk about what you're seeing there. And then I don't think that you mentioned how CRADL performed in the quarter. So maybe just walk through that as well.

    了解。這很有幫助。另外再快速問一題關於 RMS。你提到學術與政府端仍然疲弱。我們從一些工具供應商那邊聽到對該終端市場的訊號有些分歧。所以能否談談你們在那邊看到的情況?另外我想你沒有提到 CRADL 在本季的表現如何。所以也請一併說明一下。

  • Birgit Girshick - Chief Executive Officer

    Birgit Girshick - Chief Executive Officer

  • Yes, certainly. So let me start with academic and government. So this is a segment for us that primarily is being serviced by our research models and services business. It's about 15 -- it's actually about 10% of the total company, so a smaller segment of ours. What we're seeing currently is stable but not growing demand. And historically, this has been a client segment that has been a growth segment for our research models and services business.

    好的,當然。我先從學術與政府端開始。對我們而言,這個客群主要由我們的研究模型與服務(research models and services)業務來服務。它約占公司整體的 15——其實約占 10%,所以是我們較小的一個區塊。我們目前看到的是需求穩定但沒有成長。而從歷史上看,這一直是我們研究模型與服務業務中一個成長型的客群。

  • And what we are currently seeing is a little bit, I would say, uncertainty still, right? So NIH budget has been approved. Grants are coming out, but they are now multiyear. Some of the grant holders don't quite know how to work with this yet. I think this will open up more in the future. But currently, it's holding our research models business back a little bit compared to historical.

    而我們目前看到的是,我會說,仍然有一些不確定性,對吧?NIH 預算已經核准。補助金正在釋出,但現在是多年期(multiyear)。有些補助持有人還不太確定要如何因應這種模式。我認為未來會更為開放。但目前,與過往相比,這確實讓我們的研究模型業務稍微受到一些拖累。

  • And that's why we are not quite seeing the demand in -- specifically in North America that we would like to see. Looking at our CRADL business, CRADL is stable from a revenue perspective as well. But again, here, too, we're not seeing quite the growth that we historically have seen in our CRADL business. CRADL is specifically focused on new companies, new biotech companies that have funding, but do not want to spend or have enough funding to create their own vivariums.

    這也是為什麼我們目前尚未看到——特別是在北美——我們希望看到的需求水準。再看我們的 CRADL 業務,從營收角度來看,CRADL 也同樣保持穩定。但同樣地,在這裡我們也沒有看到 CRADL 業務如同過往歷史所呈現的那樣成長。CRADL 特別聚焦於新成立的公司、獲得資金的新生技公司,但他們不想投入,或資金不足以建立自有的動物房(vivarium)。

  • So we're providing them with a space to do their research early on, grow with them and then many of them leave and have their own vivariums but -- or they continue to stay with us for a few years. And this business is still a bit hindered. If you think about the company formation is growing, but only by 2% and far off from the COVID levels. So we just need to see a little bit more strengthening of that new company formation, new biotechs being established before we will see this CRADL business to return to former growth rates.

    因此我們為他們提供一個空間,讓他們在早期就能進行研究,與他們一同成長;之後其中許多公司會離開並建立自己的動物房,但——或者他們也會繼續在我們這裡待上幾年。而這項業務目前仍受到一些抑制。如果你看公司成立數量正在成長,但僅成長 2%,而且遠低於 COVID 時期的水準。所以在我們看到這類新公司成立、新生技公司設立的動能再更強一些之前,CRADL 業務不會回到先前的成長率。

  • Operator

    Operator

  • Elizabeth Anderson, Evercore ISI.

    Elizabeth Anderson,Evercore ISI。

  • Elizabeth Anderson - Analyst

    Elizabeth Anderson - Analyst

  • As we think about the bookings, which obviously was a really nice step-up to see in the quarter, can you talk a little bit more about kind of the mix of services within those bookings? Are they sort of similar to what your current revenue mix is? Are you seeing like incremental demand in certain places within DSA versus previously? Any kind of additional qualitative color there would be very helpful.

    在我們思考訂單(bookings)時,這一季顯然看到非常不錯的躍升;你能否再多談一些這些訂單中各項服務的組合(mix)?它們是否與你們目前的營收組合大致相近?相較於先前,你們是否在 DSA 的某些領域看到額外的增量需求?任何額外的定性補充都會非常有幫助。

  • Birgit Girshick - Chief Executive Officer

    Birgit Girshick - Chief Executive Officer

  • Yes, Elizabeth, happy to. So what we're seeing is a little bit of a shift from more post-IND work to more pre-IND work. Now we see this over time happening here and there in any time. But over the last few years, just because of funding was better available in later stage that post-IND had a bit more of a heavier component of our work.

    好的,Elizabeth,很樂意。我們看到的是,從較多的 IND 後(post-IND)工作,稍微轉向更多的 IND 前(pre-IND)工作。當然,這種情況在任何時期都可能零星發生、隨時間推移出現。但在過去幾年,因為後期階段的資金相對更充裕,IND 後工作在我們的業務中占比就比較高。

  • And over the last quarter, we saw that pivoting back a little bit to pre-IND work, which is great to see. We need both for the utmost profitability and capacity utilization at our company. But it is important that pre-IND work is being performed because that will just lead into later-stage work, more complex work, more specialty work. So that's actually a good sign that we are taking that the market, the funding, our clients' demand is strengthening.

    而在上一季,我們看到這個趨勢稍微轉回 IND 前工作,這是很好的現象。為了達到公司最高的獲利能力與產能利用率,我們兩者都需要。但 IND 前工作能夠被執行很重要,因為它會帶動後期階段的工作、更複雜的工作、更多專業性的工作。所以這其實是一個好訊號,代表我們認為市場、資金環境以及客戶需求正在轉強。

  • Elizabeth Anderson - Analyst

    Elizabeth Anderson - Analyst

  • Got it. And maybe as a follow-up, just to understand, how do you guys feel about any kind of incremental investment levels? I understand what you've been saying about some of the technology and AI investments really helping on that front too. But just as we kind of think about this influx of demand, anything to think about on that front? Or you sort of feel comfortable with sort of where utilization levels are and staffing levels and things like that and as we think about like the back half of '26 into 2027?

    了解。那也許追問一下,為了更好理解:你們對於任何額外的投資水準有什麼看法?我理解你一直提到一些技術與 AI 投資在這方面也很有幫助。但當我們思考這波需求湧入時,在投資層面有沒有什麼需要注意的?或者你們對目前的利用率水準、人力配置等感到足夠安心——尤其是當我們展望 2026 年下半年到 2027 年?

  • Birgit Girshick - Chief Executive Officer

    Birgit Girshick - Chief Executive Officer

  • Yes. So we are adding staffing just based on what we expect from demand. So that is always, always. We'll add the staff. We'll get them trained up and make sure they're ready for revenue to pick up. The other investments we're making, I mentioned that a little bit in my remarks, is in lab space and lab expansions. That doesn't have an impact on revenue in 2026, but it will have -- allows us to grow in that area '27 and beyond.

    是的。我們會依據對需求的預期來增加人力。所以這一直都是——一直都是如此。我們會增聘人員。我們會把他們訓練到位,確保在營收回升時他們已準備就緒。我們正在進行的其他投資——我在發言中也稍微提到——是在實驗室空間與實驗室擴建方面。這對 2026 年的營收沒有影響,但它將——讓我們能在 2027 年及之後在該領域成長。

  • So it's very important that we execute on that. I specifically talked about an expansion in Edinburgh, where we are close to one of the universities, which then also helps us with the staffing aspect. We continue to focus also on modernizing our labs, bringing more automation in, increasing the throughput and bringing systems in both digitals as well as lab equipment systems to really drive speed but also utilization in our laboratories.

    因此,確實執行到位非常重要。我特別提到愛丁堡的擴建案,我們靠近其中一所大學,這也有助於人力招募與配置。我們也持續聚焦於實驗室現代化,引入更多自動化、提升產出量(throughput),並導入系統——包括數位系統以及實驗室設備系統——以真正提升速度,同時也提升我們實驗室的利用率。

  • So we will continue to talk about that, how we will modernize the company. It's both for speed and efficiencies. But that is a big focus of ours right now in all segments and all functions. And particularly during our Investor Day, we will deep dive on that a bit more.

    所以我們會持續談論我們將如何讓公司現代化。這同時是為了速度與效率。但這是我們目前在所有事業部門與所有職能上的一大重點。尤其在我們的投資人日(Investor Day),我們會更深入地探討這部分。

  • Operator

    Operator

  • Ryan Halsted, RBC.

    Ryan Halsted,RBC。

  • Ryan Halsted - Analyst

    Ryan Halsted - Analyst

  • My question is just on the guidance raise, if you could just offer some more color on the incremental visibility you have into the bookings that you now expect to convert in the second half. I thought maybe you said this was related to bookings that you've completed the middle of this year? Or is this bookings from prior year?

    我的問題是關於上調財測(guidance):你能否就你們現在預期在下半年轉換(convert)的訂單,提供更多增量能見度方面的說明?我想也許你提到這與你們在今年年中完成的訂單有關?還是這些是前一年度的訂單?

  • Glenn Coleman - Chief Financial Officer, Executive Vice President

    Glenn Coleman - Chief Financial Officer, Executive Vice President

  • Yes, Ryan, thanks for the question. So, the confidence in the raise to our revenue and EPS is really based upon the bookings we saw come through in Q2. So most of the year now we've got in bookings. We still have to see a book-to-bill of 1 or greater for the rest of the year, but that's largely going to impact 2027. We'll get some benefit from that in the second half of the year.

    是的,Ryan,謝謝你的問題。所以,我們對營收與 EPS 上調的信心,主要是基於我們在第二季看到進來的訂單。因此,今年大部分的訂單我們現在都已經拿到了。今年剩餘期間我們仍需要看到接單對出貨比(book-to-bill)達到 1 或以上,但那主要會影響 2027 年。我們在今年下半年也會從中獲得一些好處。

  • But just given the strength we're seeing in all the key lead indicators, net book-to-bill being one, proposal volumes being a second, capture rate being the third, we feel confident now that we're going to see better performance in the second half of the year. And so the guidance raise for EPS is all associated with revenue, and we raised our organic revenue growth rate by about 150 basis points.

    但考量到我們在所有關鍵領先指標上看到的強勁表現——淨接單對出貨比是一項、提案量(proposal volumes)是第二項、得標率(capture rate)是第三項——我們現在有信心下半年會看到更好的表現。因此,EPS 的財測上調完全是與營收相關,我們把有機營收成長率上調了大約 150 個基點。

  • Ryan Halsted - Analyst

    Ryan Halsted - Analyst

  • Got it. That's helpful. And then my follow-up, just in terms of your modernization initiatives, some of the detail you provided in the prepared remarks was very helpful. But I wanted to ask specifically about NAMs. Any -- should we be looking for kind of collaborations and partnerships with biotech companies that maybe have some interesting innovation in kind of NAMs? Appreciate that.

    了解。這很有幫助。那我的追問是,關於你們的現代化計畫,你在事先準備的發言中提供的一些細節非常有幫助。但我想特別問 NAMs。我們是否應該期待你們與生技公司展開某種合作與夥伴關係——例如在 NAMs 方面有一些有趣創新的公司?謝謝。

  • Birgit Girshick - Chief Executive Officer

    Birgit Girshick - Chief Executive Officer

  • Yes. So we have a very strong NAMs focus and commitment. So we -- last year, we established a Scientific Advisory Board. We hired a leader from the industry to be our Chief Scientific Officer and to particularly focus on NAMs development. And so what we are doing is really focusing on areas where we believe NAMs can have a benefit on the reduction of animals, but also providing more insights, more evidence to our clients.

    是的。我們對 NAMs 有非常強的聚焦與承諾。所以——去年我們成立了科學諮詢委員會(Scientific Advisory Board)。我們從產業中聘請了一位領導者擔任我們的首席科學官(Chief Scientific Officer),並特別聚焦於 NAMs 的開發。因此,我們正在做的是,真正聚焦在我們相信 NAMs 能夠帶來效益的領域:一方面減少動物使用,另一方面也為客戶提供更多洞見與更多證據。

  • And it's going to be a very broad mix of technologies, assays that we are -- either already have or are developing or in-licensing or partnering with. So you will see probably more internal development, followed by licensing and partnering. So you will probably hear us talk about some of the technologies that we are in-licensing and partnering.

    而這將會是非常廣泛的技術與檢測(assays)組合;我們——要嘛已經擁有、要嘛正在開發、要嘛透過引進授權(in-licensing)或合作夥伴關係取得。所以你們可能會看到更多的內部開發,接著是授權引進與合作。因此你們大概也會聽到我們談到一些我們正在引進授權與合作的技術。

  • And then we also are working with several of our clients on areas where they are interested or where they see the best possible outcomes. So it's ongoing. Again, during our Investor Day, we'll give a deep dive on NAMs development, how we think about it, where we do see opportunities. There will never be a NAMs business for Charles River.

    接著,我們也正與數位客戶在一些他們感興趣、或他們認為能帶來最佳成果的領域上合作。因此這是持續進行中的。同樣地,在我們的投資人日,我們會深入說明 NAMs 的發展、我們如何看待它,以及我們在哪些地方看到機會。Charles River 永遠不會有一個獨立的 NAMs 業務。

  • It will always be a Safety Assessment business where we're integrating NAMs into our Safety Assessment workflows. And I think that is the strength and that is the only way NAMs can be adopted. And we're in a really good position to be the leader in the integration. And as I said, it will be from multiple sources, multiple technologies, not really focused on one single thing.

    它將永遠是一個安全性評估(Safety Assessment)業務,我們會把 NAMs 整合進我們的安全性評估工作流程中。我認為這就是優勢所在,也是 NAMs 能被採用的唯一方式。而我們在整合方面處於非常有利的位置,能成為領導者。而且如我所說,它會來自多個來源、採用多種技術,不會只聚焦在單一項目上。

  • Operator

    Operator

  • Luke Sergott, Barclays.

    Luke Sergott,巴克萊。

  • Luke Sergott - Analyst

    Luke Sergott - Analyst

  • Just wanted to ask about the -- if you guys are seeing any demand pickup from the DoD list in the WuXi on the no (technical difficulty) list. I know that was in June, but any signs of early wins or conversations with those customers?

    我想問一下——你們是否看到來自國防部(DoD)名單、以及 WuXi 被列入不(技術問題)名單後所帶來的需求回升。我知道那是在六月,但是否有任何早期的斬獲或與那些客戶的對話跡象?

  • Birgit Girshick - Chief Executive Officer

    Birgit Girshick - Chief Executive Officer

  • Yes. Luke, so generally, most of that work that they're doing is in the early stage like chemistry biology that we are no longer in the business of. So I couldn't tell you specifically if clients are looking for other providers there. But I'm assuming there are. We had a few discussions with clients more in the regulated space. But generally, the Western clients are not yet taking their regulated work to China. And so those discussions are quite limited, but not occurring. So if that's English. So limited, but yes, a little bit.

    有的。Luke,一般來說,他們在做的大多是早期階段的工作,例如化學、生物學,而我們已經不再從事這類業務。所以我無法具體告訴你,客戶是否正在那一塊尋找其他供應商。但我推測是有的。我們與一些客戶有過幾次討論,更多是在受監管的領域。但整體而言,西方客戶目前仍未把其受監管的工作帶到中國。因此這些討論相當有限,但並非完全沒有發生。所以如果那是英文的話。所以有限,但有,一點點。

  • Luke Sergott - Analyst

    Luke Sergott - Analyst

  • Okay. Perfect. And then on the guide with the DSA business and in light of your strong bookings, kind of implies there a decel in the conversion or burn rate. So anything there from a mix perspective or how the projects are shaking out that gives you that decel? Or is that just kind of the conservatism based on what you guys are seeing right now?

    好的。非常好。另外,關於 DSA 業務的指引,在你們訂單表現強勁的情況下,似乎暗示轉換率或消化(burn)速度會放緩。那麼從組合角度,或專案進展的情況來看,有什麼因素導致你們預期這種放緩嗎?還是這只是基於你們目前所見情況而採取的保守作法?

  • Birgit Girshick - Chief Executive Officer

    Birgit Girshick - Chief Executive Officer

  • It's more about the time it takes to go from bookings -- for proposal to bookings, bookings to revenue generating. And then that just will take some time. So some of the work we are doing is still booked -- was booked last year. And what you're seeing now, the demand or the net book-to-bill really will have an impact in the second half into '27. So it's just a matter of timing.

    這更多是關於從訂單——從提案到訂單、從訂單到開始產生營收所需的時間。而這需要一些時間。所以我們目前在做的一部分工作,仍然是去年就已簽下的——是在去年就已入帳的訂單。而你現在看到的需求或淨訂單出貨比(net book-to-bill),真正的影響會在下半年一路延伸到 2027 年。所以這只是時間點的問題。

  • Glenn Coleman - Chief Financial Officer, Executive Vice President

    Glenn Coleman - Chief Financial Officer, Executive Vice President

  • And keep in mind, for the first half of the year, DSA had negative organic growth, and now we're projecting low single-digit organic growth in the back half of the year. So we are reflecting some of that improvement here. And obviously, we'd like to see that continue to accelerate going into 2027.

    另外請記住,上半年 DSA 的有機成長為負,而現在我們預期下半年會是低個位數的有機成長。因此我們在這裡反映了部分改善。當然,我們也希望這種改善能持續加速,延續到 2027 年。

  • Operator

    Operator

  • Joshua Waldman, Cleveland Research.

    Joshua Waldman,Cleveland Research。

  • Josh Waldman - Analyst

    Josh Waldman - Analyst

  • I'll just keep it to one. Birgit, it sounds like you feel comfortable with existing safety capacity. I mean when you think about your ability to get better utilization on existing capacity, the impact of NHP costs, et cetera, how do the moving pieces leave you feeling on the margin setup into next year? Or I guess, how are you thinking about the margin potential for the business in Q4 and into '27?

    我就問一個問題。Birgit,聽起來你對現有的安全性產能感到放心。當你思考提升既有產能利用率的能力、NHP(非人靈長類)成本的影響等等,這些變動因素如何影響你對明年利潤率架構的看法?或者說,你如何看待 Q4 以及一路到 2027 年的業務利潤率潛力?

  • Birgit Girshick - Chief Executive Officer

    Birgit Girshick - Chief Executive Officer

  • I think we're going to stay away from comments on 2027. That's a little bit early. There are some areas, obviously, that we already called out, which, for example, the KF Cambodia acquisition and divestitures have a positive impact on margin next year, and we can walk you through. But overall, I want to stay away. There's too many variables in play that we still need to work through.

    我想我們會避免對 2027 年發表評論。現在談還太早。當然,有些領域我們已經點出來了,例如 KF 柬埔寨收購案以及資產剝離,明年會對利潤率帶來正面影響,我們可以帶你逐一說明。但整體而言,我想先不談。仍有太多變數在作用中,我們還需要進一步梳理。

  • For the second half of the year, we called out at least 500 basis points, a big impact in Q4 because of when the nonhuman primates are coming through on the revenue line. But I wouldn't necessarily translate that straight into 2027. So Glenn, you can start --

    就今年下半年而言,我們提到至少 500 個基點;由於非人靈長類在營收端入帳的時間點,Q4 的影響會很大。但我不會把這直接套用到 2027 年。所以 Glenn,你可以先開始——--

  • Glenn Coleman - Chief Financial Officer, Executive Vice President

    Glenn Coleman - Chief Financial Officer, Executive Vice President

  • No, no, exactly. Don't take the Q4 run rate and assume that that's the run rate going forward. I think year-over-year '27 versus '26, if you look at some of the previous comments we've made, we would expect to see some margin expansion coming from the full impact of divestitures and the Cambodia acquisition. So that will have a tailwind in '27, but we're not ready to yet give guidance on our margins for next year.

    不,不,沒錯。不要拿 Q4 的運行率(run rate)就假設那會是未來的運行率。我認為 2027 年相較 2026 年的年對年表現,如果你回顧我們先前的一些評論,我們預期利潤率會有一些擴張,來源是資產剝離的完整影響以及柬埔寨收購案的完整影響。因此 2027 年會有順風,但我們還沒準備好提供明年利潤率的指引。

  • Operator

    Operator

  • We have no further questions in queue. I will now turn the conference back to Todd Spencer for closing remarks.

    目前沒有更多排隊中的問題。我現在把會議交回給 Todd Spencer 作結語。

  • Todd Spencer - Corporate Vice President, Investor Relations

    Todd Spencer - Corporate Vice President, Investor Relations

  • Thank you for joining us on the conference call this morning. For those interested in our Investor Day on September 24, please visit the Investor Relations section of our website at ir.criver.com to register for the webcast or contact me for any additional details. This concludes the conference call. Thank you.

    感謝各位今天早上參加我們的電話會議。對於有興趣參加 9 月 24 日投資人日的各位,請造訪我們網站的投資人關係專區 ir.criver.com 註冊收看網路直播,或聯絡我以取得任何其他細節。本次電話會議到此結束。謝謝。

  • Operator

    Operator

  • Thank you. That does conclude today's Charles River Laboratories second-quarter 2026 earnings call. Thank you for your participation, and you may now disconnect.

    謝謝。今天的 Charles River Laboratories 2026 年第二季財報電話會議到此結束。感謝各位的參與,現在可以掛線。